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Chapter 1
General introduction
8 Chapter 1
Osteoarthritis
Osteoarthritis (OA) is a chronic disease of the knee joint, causing pain, joint 
stiffness and functional impairment.1, 2  The incidence and prevalence of 
OA has risen in recent decades, including increasing numbers of younger 
patients suffering from OA.3, 4 In 2010, together with hip OA, knee OA was 
ranked as the 11th highest contributor to global disability among the 291 
investigated conditions.5 Worldwide, knee OA was estimated to account for 
approximately 85% of the burden of disease for OA.6 In The Netherlands, 
the prevalence of OA was estimated around 1.4 million patients in 2017, on 
a total population of around 17 million inhabitants at that time. Of these 
patients, 0.6 million patients suffered from knee OA which makes knee OA 
the most prevalent type of OA in The Netherlands.7 
Although often referred to as a local degenerative disorder due to what 
is popularly denominated as wear of the cartilage, OA is a disease of the 
whole joint involving all joint tissues.8, 9 Not only the intra-articular cartilage 
is affected, but also bone, menisci, ligaments and synovium are involved in 
several biological processes leading to structural changes throughout the 
joint.8, 9 These changes comprehend loss of intra-articular hyaline cartilage, 
meniscal damage, subchondral bone sclerosis and osteophyte formation, 
but also inflammation of the synovium, degradation of the synovial fluid, 
laxity of the ligaments and muscle weakness of the surrounding muscles.8-11 
Several biochemical and biomechanical factors contribute to the development 
of OA. These factors include age, gender, genetic predisposition, obesity, 
previous joint damage and specific injurious activities.9, 10 For knee OA, 
evidence indicates a variety of moderate to strong specific risk factors like 
female sex, obesity, previous knee injury and knee malalignment.12 
Occupational factors also play a role in the etiology of knee OA. For example, 
occupations that require physical activities like knee bending, kneeling, squatting 
and heavy lifting are associated with an increased risk for knee OA.13, 14
Economic consequences
Osteoarthritis has serious economic consequences. The rising prevalence 
and incidence of the disease in recent years has led to much higher overall 
spending for OA.3, 15  The economic burden of OA consists of medical and 
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productivity costs.16-18 Medical costs, or direct costs, refer to the costs from 
all resources consumed in the health care sector and patients’ out of pocket 
expenses due to the disease.16-19 Productivity costs, or indirect costs, are 
mainly subdivided in costs due to lost productivity while being present at work 
(presenteeism),20-22 or costs due to absence from work (absenteeism).23, 24 Costs 
related to the unpaid labor from caregivers in informal care or community 
care are generally also considered part of the productivity costs.16, 25
In the Netherlands, the total medical costs related to OA in 2015 were 1.3 
billion euro. This equals 1.6% of the overall healthcare costs at that time.26 
The total medical costs related to knee OA in 2015 were estimated at 
0.4 billion euro.26 No studies on productivity costs related to knee OA for 
the Dutch situation were available before the onset of the investigations in 
this thesis. A systematic review on studies from nations worldwide reported 
that productivity costs for lower limb OA are lower than the medical cost.27 
Heterogeneity and lack of methodologic consensus between the included 
studies prohibited reliable estimates of the cost-of-illness in this study.27
Diagnosis
Knee OA can be diagnosed based on clinical findings, sometimes in 
combination with additional radiological investigations.28-30 Typical symptoms 
of knee OA include persistent knee pain, short-term morning stiffness and 
functional impairments. During physical examination of the knee, crepitus, 
restricted movement and bony enlargements can be found.30  The guideline 
from the Dutch Federation of Medical Specialists states that knee OA can be 
diagnosed based on the presence of clinical findings only. Routine imaging 
procedures are not recommended in the diagnostic work-up in knee OA.28, 29
If radiographic imaging is needed, plain radiography (X-ray) should be made 
in weight-baring position and additional weight-bearing position with the 
knee flexed in 45° (the Rosenberg view).31-33  Radiographic signs of knee OA 
seen on plain radiographs are joint space narrowing, osteophyte formation, 
sclerosis of the subchondral bone and the presence of cysts.34 To further 
investigate soft tissue, bony and/or cartilage pathology, other imaging 
modalities like ultra sound (US), computed tomography (CT) and magnetic 
resonance imaging (MRI) are available.29
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Radiographic knee OA is graded with the Kellgren and Lawrence (K&L) score. 
This score grades radiographic findings from 0 (no radiographic features of 
OA) to 4 (severe radiographic features of OA).35 Although widely used, the 
K&L score has its limitations. The results of plain radiographs should not 
be used in isolation when assessing individual patients with suspected knee 
OA.36-39
Non-surgical treatment
The non-surgical treatment of knee OA is purely symptomatic. Disease 
modifying drugs with the ability to slow down, stop or even reverse disease 
progression are in a developmental stage and currently unapproved for 
therapeutic purposes.12 The guidelines of stakeholder organizations in the 
field of knee OA mostly agree upon several recommendations concerning 
the non-surgical treatment of knee OA.40 Treatment modalities like exercise 
therapy (land- or water-based), weight reduction in case of overweight and 
self-management and education are generally recommended for the non-
surgical treatment of knee OA.12, 40, 41 Biomechanical interventions like walking 
aids are recommended in appropriate circumstances, as are topical and/
or oral non-steroidal anti-inflammatory drugs (NSAIDs) and intra-articular 
corticosteroids. Controversy exists about the use of knee braces and heel 
wedges, whereas acupuncture and glucosamine or chondroitin are mostly 
not recommended in the non-surgical treatment of knee OA.12, 40, 41
Hyaluronic acid as a treatment modality
An alternative treatment for symptomatic knee OA is intra-articular 
injection therapy with hyaluronic acid (HA, or hyaluronan), also known as 
viscosupplementation therapy.42-44 
HA is a glycosaminoglycan molecule naturally found in the synovial fluid of 
joints. In the healthy knee joint, the synovial fluid contains HA macromolecules 
with a molecular weight (MW) ranging between 4-10 mega Daltons (mDa).45 
HA is constantly secreted into the joint and removed by the synovium in 
a natural turn-over process, with a half-life time of endogenous HA in the 
joint of around 12 hours.45-47 Due to its shear-dependent viscosity, HA acts 
as a lubricant and shock absorber, protecting the articular cartilage from 
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compressive and shear forces. During joint loading, a gel structure of 
micrometric thickness is formed by which HA contributes to the protection 
of the cartilage surfaces from frictional damage. The synovial fluid supplies 
oxygen and nutrients to the surrounding tissues and removes carbon 
dioxide and metabolic wastes. The HA molecules act as a filter by restricting 
the entrance of large plasma proteins into the synovial fluid, while facilitating 
the passage of small molecules into the joint for maintenance of nutrition.45-47 
In the osteoarthritic knee, acceleration of the natural turn-over process of HA 
occurs under inflammation and oxidative stress. This pathological process 
results in a breakdown of the intact HA molecule into low molecular weight 
HA-fragments, which leads to an impairment of the viscoelastic properties of 
the HA molecules in the synovial fluid.47
Viscosupplementation therapy is based on the rationale that the degraded 
synovial fluid in the osteoarthritic knee is replaced or supplemented with an 
exogenous elastoviscous fluid. This fluid is composed of an HA derivative 
that has similar rheological properties compared to healthy synovial fluid.42, 48, 
49 The decreased rheological properties of the original pathological synovial 
fluid are recovered, resulting in restoration of shock absorption during 
movement and protection of the extracellular matrix of the cartilage.42, 45, 48, 49
Research on the possible therapeutic effects of viscosupplementation in 
the human osteoarthritic knee started in the late 1960s and early 1970s.49, 
50 Initially, the clinical beneficial effects were attributed to the direct intra-
articular administration of the HA-derivative and the following restoration of 
fluid elasticity and viscosity.42 Nevertheless, the half-life time of exogenous 
administered HA appeared to be short, varying from 48 hours to about 7 
days depending on the MW  and structure of the derivative.45 Over time, 
other biochemical mechanisms of action were found including effects of 
the administered HA-derivative on the extracellular matrix, immune cells, 
inflammatory mediators and the nociception of the arthritic joint.45
HA products for clinical use in knee OA are mostly produced by either 
bacterial fermentation or extracted from avian tissue like rooster combs.51 In 
order to increase molecular weight and prolong the half-life time in the knee 
joint the molecular structure of HA can be chemically crosslinked to form so-
called Hylans.52 
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In clinically manifest knee OA intra-articular HA results in pain reduction 
and improvement of knee function.44 Several approaches are available 
to establish the intra-articular needle placement in the knee joint for the 
eventual administration of the HA derivative.53, 54 
The beneficial effects on pain reduction are similar to NSAID use and 
larger than intra-articular corticosteroids on the longer term.55-57 Treatment 
with NSAIDs is related to an increased risk of serious gastrointestinal and 
cardiovascular side effects, indicating limited use of NSAIDs only.58, 59 
The peak effectiveness of a series of intra-articular injections with HA is 
reached between 1 and 2 months with residual effects up to 6 months.43, 44, 60
Intra-articular HA for knee OA is generally considered being safe. Adverse 
effects mostly consist of transient local reactions like pain, effusion or flare 
like symptoms.44, 61 Within the spectrum of available HA derivatives, there is 
increasing evidence that the efficacy of HA products with a high molecular 
weight (HMW) is superior to the efficacy of derivatives with a low molecular 
weight.61, 62 
Overall, treatment with intra-articular HA appears to result in a favorable 
benefit-risk balance in the treatment of knee OA compared to other 
pharmacological treatments.63
Nevertheless, controversy on the use of HA in knee OA exists.  The clinical 
relevance of the effect size of HA in knee OA has been questioned in a systematic 
review and meta-analysis on the topic.64 National and international OA 
management guidelines are ambiguous in their recommendation concerning 
intra-articular HA as a treatment modality for symptomatic knee OA.28, 40 
Aims and outline of this thesis
This thesis focuses on various aspects of intra-articular HA as a non-surgical 
treatment modality for patients with knee OA.
In chapter 2 we describe a systematic review on the accuracy of different 
approaches for intra-articular injections in the knee joint.
In chapter 3 we identified and quantified the productivity costs and medical 
costs in knee OA patients with a paid employment. We also investigated the 
associations between productivity losses and relevant patient, health, and 
work characteristics.
13General introduction
1
A randomized clinical trial was designed to investigate the effectiveness as well 
as the cost-effectiveness of intra-articular HA added to the usual non-surgical 
care for symptomatic knee OA: the VISK study.  Patients between 18 and 65 
with symptomatic knee OA were randomized in either the intervention group 
who received 3 weekly injections with a HMW HA derivative added to the 
usual care, or in the control group who received usual care only. In chapter 
4 we report on the clinical effectiveness results of the VISK study. The primary 
clinical outcome was defined as response to therapy at 52 weeks follow-up 
according to OMERACT-OARSI criteria. This variable presents the results of 
changes after treatment in three symptomatic domains (pain, function, and 
patient global assessment (PGA)) as a single variable. Chapter 5 presents 
the economic evaluation results of the VISK study. A cost-utility analysis was 
performed in order to determine the cost-effectiveness of intra-articular HA 
added to the usual non-surgical care for knee OA patients. The primary health 
economic outcome was determined by the between group difference in 
quality-adjusted life years (QALYs) and the between group difference in costs. 
The differences in mean adjusted QALYs and costs between the 2 treatment 
groups were expressed in a so-called incremental cost-effectiveness ratio 
(ICER), which is interpreted as the additional costs per QALY gained due to 
the intervention. Given various thresholds for the maximum willingness to 
pay for 1 QALY gained, the probability of cost-effectiveness of intra-articular 
HA therapy in knee OA was then indicated on an acceptability curve. 
In chapter 6 we present the results of a systematic review on the adverse 
effects of intra-articular treatment with HA in the knee. We describe the 
association of these adverse events with several product characteristics of 
different HA derivatives available.
Chapter 7 discusses the main findings of the research in this thesis. 
Limitations are addressed. Implications from a clinical as well as from a 
health-economic point of view are discussed as well as possible directions 
for future research.
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Abstract
Introduction
Intra-articular needle placement in the knee joint such as injection or 
aspirations are commonly used for therapeutic, diagnostic and research 
purposes concerning knee pathology. Although several approaches can be 
used to establish an intra-articular injection or aspiration of the knee joint, 
the accuracy differs per approach. 
Objective
To summarize the evidence concerning the accuracy of different approaches 
for intra-articular needle placements in the knee. Additionally, to assess 
whether the accuracy of different approaches is related to factors such as 
underlying disease, severity of underlying disease, approach-related factors 
and/or to the rate of local reactions.
Methods
The literature was systemically reviewed until July 2010. Risk of bias of the 
included studies was assessed by the QUADAS tool. Study characteristics 
were extracted, accuracy results were pooled per approach.
Results
Nine studies were included. The superolateral approach with the leg in 
extension was studied most (230 injections) and resulted in the highest 
pooled accuracy of 91% (95% CI 84-99%). The lateral midpatellar approach, 
the anterolateral approach and the anteromedial approach resulted in the 
lowest pooled accuracy rates, 85% (95% CI 68-100%), 67% (95% CI 43-91%) 
and 72% (95% CI 65-78%), respectively.
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Conclusions
The superolateral approach was investigated most and resulted in the highest 
pooled accuracy rate of 91% (95% CI 84-99%). Nevertheless, this approach 
still results in a substantial amount of extra-articular needle placements. 
Guidance of intra articular needle placements by imaging techniques may 
enhance the accuracy. The costs and extra time associated with these 
techniques should be taken in consideration.
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Introduction
Intra-articular needle placements such as injections or aspiration of the knee 
joint are commonly used in clinical practice by physicians like rheumatologists, 
orthopaedic surgeons and general practitioners. In treatment modalities for 
knee joint disorders such as rheumatoid artritis (RA) and osteoarthritis (OA), 
intra-articular injections, eg, with corticosteroids can be required. Treatment 
guidelines for knee OA1 furthermore include intra-articular therapy with 
hyaluronic acid (HA) based on increasing evidence of their efficacy.2-7 HA 
is assumed to give the optimal result when injected directly into the cavity 
of the knee joint.8-10 In the diagnostic process of gout, pseudo gout and 
bacterial arthritis, an intra-articular procedure such as knee joint aspiration 
can be necessary.11 Furthermore, when severe swelling or a bacterial arthritis 
is present, knee joint aspiration may be required. For research purposes of 
e.g. synovial fluid, aspiration of the knee can also be performed.11 In all the 
aforementioned, an accurate intra-articular localisation of the needle is of 
considerable importance. 
Although several approaches to establish an accurate intra-articular needle 
placement in the knee joint are available,12, 13 success rates of the different 
approaches are not optimal14 and accuracy rates differ per approach.10, 15, 
16 Moreover, in the treatment of OA with intra-articular HA the rate of local 
reactions seems to be associated with the approach used.4 
To date, no systematic review on the accuracy of different approaches of 
intra-articular needle placements in the knee joint has been published. A 
structured overview of this topic will be helpful to physicians performing 
intra-articular injections or aspiration of the knee in their practice.
Therefore, this systematic review summarizes the evidence regarding the 
accuracy of different approaches for intra-articular needle placements such 
as injections or aspiration of the knee joint. Additional objectives are to 
assess whether the accuracy of different approaches is related to factors 
such as underlying disease, severity of underlying disease, approach-related 
factors and/or to the rate of local reactions.
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Methods
Identification of studies
To identify all studies addressing the accuracy of approaches for intra-
articular needle placements in the knee joint, a systematic search was 
conducted in Pubmed and Embase since their inception up to July 2010. The 
search strategy is shown in Appendix 1. Reference tracking was performed 
to identify additional suitable studies not identified by the conducted search 
strategy.
The result of the search strategy was independently analysed for suitable 
articles by 2 of the reviewers (JH, MR). If both reviewers failed to achieve 
consensus the opinion of a third reviewer (JV) was available for final judgment, 
but was in fact not required. 
A study was included when it met the following inclusion criteria:
• Study subjects were human or human cadavers; 
• The study addressed the accuracy of a certain approach of intra-
articular injection or intra-articular needle placement in the knee joint;
• An adequate reference method was used to ascertain intra-articular 
injection or needle placement in the knee joint; 
• The article presented original data, or original data could be obtained 
from the authors; 
• The article was written in Dutch, Spanish, French, German, English, 
Polish, Swedish, Danish or Norwegian; and 
• Full text of the article was available. 
Studies were excluded when concerning a review, systematic review or meta-
analysis.
Risk of bias assessment    
Risk of bias of the included studies was assessed by the QUADAS tool17 
(Table 1). This tool provides a standardised approach of quality assessment 
in diagnostic accuracy studies and has demonstrated good interrater 
reliability.17, 18 It consists of 14 items17, 18 and can be extended with 9 potential 
additional items19 which all can be scored by ‘yes’, ‘no’ or ‘unclear’. The 14 items 
refer to the spectrum of patients, reference standard, disease progression 
bias, verification bias, review bias, clinical review bias, incorporation bias, 
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test execution, study withdrawals and indeterminate results. The 9 potential 
additional items refer to technology development, observer and instrument 
variation, specification of objectives, definitions and cut-off values, skills 
level of test operators, treatment during testing and commercial funding. All 
studies were scored independently by 2 of the reviewers (JH, SBZ). In case 
of disagreement, both reviewers tried to achieve consensus. If not achieved, 
a third reviewer (JV) was available to make a final judgment but, again, this 
proved unnecessary.
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Table 1  Items in the QUADAS tool
Item Yes No Unclear
1. Was the spectrum of patients representative of the patients who will 
receive the test in practice?
[] [] []
2. Were selection criteria clearly described? [] [] []
3. Is the reference standard likely to correctly classify the target condition? [] [] []
4. Is the time period between reference standard and index test short 
enough to be reasonably sure that the target condition did not 
change between the two tests?
[] [] []
5. Did the whole sample or a random selection of the sample, receive 
verification using a reference standard of diagnosis?
[] [] []
6. Did patients receive the same reference standard regardless of the 
index test result?
[] [] []
7. Was the reference standard independent of the index test (i.e. the 
index test did not form part of the reference standard)?
[] [] []
8. Was the execution of the index test described in sufficient detail to 
permit replication of the test?
[] [] []
9. Was the execution of the reference standard described in sufficient 
detail to permit its replication?
[] [] []
10. Were the index test results interpreted without knowledge of the 
results of the reference standard?
[] [] []
11. Were the reference standard results interpreted without knowledge 
of the results of the index test?
[] [] []
12. Were the same clinical data available when test results were 
interpreted as would be available when the test is used in practice? 
[] [] []
13. Were uninterpretable/intermediate test results reported? [] [] []
14. Were withdrawals from the study explained? [] [] []
15. Were cut-off values established before the study was started? [] [] []
16. Is the technology of the test unchanged since the study was carried out [] [] []
17. Did the study provide a clear definition of what was considered a 
positive result?
[] [] []
18. Had test operators had appropriate training [] [] []
19. Was treatment withheld until both the index test and reference 
standard were performed?
[] [] []
20. Were data on observer variation reported and within acceptable range? [] [] []
21. Were data on instrument variation reported and within acceptable 
range?
[] [] []
22. Were objectives pre-specified? [] [] []
23. Was the study free of commercial funding? [] [] []
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Data extraction
Study characteristics (design, study population characteristics), accuracy 
data, other outcome measures, results and conclusions were extracted from 
the included articles by two of the reviewers (JH, KB). Agreement on data 
extraction was reached by consensus. 
Data analysis
A trained statistician performed the meta-analysis using R 2.11.  Accuracy 
rates of the included studies were pooled per used approach when 
approaches were investigated more than once. In these cases a random 
effects model was applied in the pooling procedure. An intra-articular needle 
placement was considered accurate when intra-articular presence of the 
needle or injected fluid was confirmed by an adequate reference test. In the 
meta-analysis, 95% confidence intervals (CI) for all (pooled) accuracy rates 
were calculated according to Wilson. 
Results
Studies included
Our search strategy resulted in 1939 identified abstracts. The authors of 2 
articles20, 21 were contacted to provide further data concerning the number 
of injections per used approach and the used approach respectively. 
Subsequently, 8 studies met the inclusion criteria. Reference tracking of 
potentially relevant articles resulted in 1 suitable article. Therefore, a total of 9 
articles were included (Figure 1); their characteristics are presented in table 2. 
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Figure 1 Search strategy
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Table 2 Characteristics of the 9 included studies 
First 
author,
year of 
publication
Study 
population
No. of 
subjects
(no. of 
injections)
Approach
(no. of 
injections)
Index test Reference test
Bliddall22 
1999
OA;
K&L ≥ II;
no effusion
38 (56)a SL (56) Air injection Air & 
radiograph
Esenyel16 
2007
Cadavers 78 (312)b LMP (78);
MMP (78);
AL (78);
AM (78)
Needle placement 
and methylene 
blue injection
Methylene 
blue and 
needle 
detection 
after surgical 
dissection
Glattes20 
2004
Clinical 
indication for 
knee injection;
effusion
10 (10) SL (10) Contrast solution 
injection
Contrast & 
radiograph
Jackson15 
2002
Symptomatic 
degenerative 
joint disease;
no effusion
80 (240)c LMP (80);
AL (80);
AM (80)
Contrast solution 
injection
Contrast & 
radiograph
Lopes21 
2008
RA;
synovitis
32 (37) SL (37) Contrast solution 
injection
Contrast & 
radiograph
Luc23
2006
Symptomatic 
OA;
no effusion
33 (33) SL (33) Lidocaine + 
contrast solution 
injection
Contrast & 
radiograph
Toda10 
2008
Medial OA > 
lateral OA;
K&L ≥ II;
no effusion
50 (150)c SL (50);
AM (50);
MWA (50)
Hyaluronan + 
contrast solution 
injection
Contrast & 
radiograph
Waddell24 
2001
History of knee 
problems  (6 
knees);
no effusion
11 (20) WA (20) Contrast solution 
injection
Contrast & 
radiograph
Wind 25 
2004
Presenting 
for routine 
arthroscopy;
effusion not 
excluded
131 (131) SL (44);
SM (43);
AL (44)
Methylene blue 
injection
Methylene 
blue 
detection 
through 
arthroscopy
SL, superolateral approach, leg in extension; SM, superomedial approach, leg in extension; LMP, lateral 
midpatellar approach, leg in extension; MMP, medial midpatellar approach, leg in extension; AL, anterolateral 
approach, leg in 900 flexion; AM, anteromedial approach, leg in 900 flexion; WA, Waddell’s approach, 
anterolateral with leg in 30o-40o flexion; MWA, modified Waddell’s approach, anteromedial with leg in 30o 
flexion and ankle traction towards lateral; OA, osteoarthritis; RA, rheumatoid arthritis; K&L, Kellgren and 
Lawrence scale. aOne or two knees per subject, one injection per knee. bTwo knees per subject, two injections 
per knee. cOne knee per subject, three injections per knee. 
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The number of patients enrolled in the included studies ranged from 
11-131 and the number of knees examined ranged from 20-240. The study 
population of the studies consisted of patients with degenerative joint 
disease or OA (4 studies10, 15, 22, 23), RA (1 study21), a clinical indication for 
knee injections (1 study20), a range of knee problems in 6 out of 20 injected 
knees (1 study24) and an indication for routine arthroscopy (1 study25). One 
study investigated cadaver subjects (1 study16). In 7 studies, radiographic 
verification of intra-articular location of an injected contrast agent10, 15, 20, 21, 23, 
24 or injected air22 was used. In 1 study25 the amount of visible injected intra-
articular methylene blue was classified during arthroscopy. The study which 
investigated cadaver subjects16 also injected methylene blue in the knee; 
thereafter, the knee joint was dissected and the actual position of the needle 
and the amount of intra-articular staining of methylene blue was visualized. 
Risk of bias assessment
Table 3 presents the final results of the risk of bias assessment. The 2 
reviewers (JH, SBZ) had 10 unique disagreements which were resolved in a 
single consensus meeting. Overall, the QUADAS tool showed little distinction 
between the included studies.
30 Chapter 2
Table 3 Risk of bias assessment
First author, Year of publication
QUADAS 
item
Bliddall22 
1999
Esenyel16 
2007
Glattes20
2004
Jackson15
2002
Lopes21
2008
Luc23
2006
Toda10
2008
Waddell24
2001
Wind25
2004
1. yes yes unclear no yes yes yes no no
2. yes no yes no yes yes yes unclear yes
3. yes unclear yes unclear yes yes yes yes yes
4. yes yes yes yes unclear yes yes yes yes
5. yes yes yes yes yes yes yes yes yes
6. yes yes yes yes yes yes yes yes yes
7. yes yes yes yes yes yes yes yes yes
8. yes yes yes yes yes yes yes yes yes
9. yes yes yes yes yes yes yes yes yes
10. yes yes yes yes yes yes yes yes yes
11. no no yes no yes no no yes no
12. na na na na n.a na na na na
13. yes yes yes yes yes yes yes yes yes
14. yes yes yes yes yes yes yes yes yes
15. na na na na n.a na na na na
16. na na na na n.a na na na na
17. unclear no yes yes yes yes yes yes yes
18. unclear unclear unclear yes yes unclear yes unclear yes
19. na na na na n.a na na na na
20. no no no no unclear no unclear no unclear
21. na na na na n.a na na na na
22. yes yes yes yes yes yes yes yes yes
23. yes unclear yes yes yes unclear yes unclear yes
Question 1 was scored ‘yes’ when one of the following conditions applied to the study population: RA, OA, 
synovitis, bursitis, swollen knee or any other well-defined condition that requires intra-articular therapy. 
Question 2 was scored ‘yes’ when at least 2 of the following were well described in the reviewed article: 
setting in which the study took place, age of the study population and underlying condition of the study 
population. Question 3 was scored ‘yes’ when the reference standard consisted of ultrasonography, computed 
tomography (CT), magnetic resonance imaging (MRI), fluoroscopy, arthrography or arthroscopy. Question 4 
was scored ‘yes’ when elapsed time between reference standard and index test did not exceed 2 hours. 
Question 18 was scored ‘yes’ when injections were performed by an orthopaedic surgean, rheumatologist, 
sports doctor or trained other person. Question 22 was scored ‘yes’ when the objective was accuracy of an 
intra articular injection or needle placement in the knee. Questions 12, 15, 16, 19 and 21 were considered not 
applicable (n.a) for all included studies.
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Study results
The different approaches used in the included studies are shown in Figure 
2. Table 4 presents an overview of the accuracy results per used approach. 
Due to the practical performance of the injection procedure, the so-called 
lateral patellar approach studied by Toda and coworkers10 was categorized in 
the superolateral approach group. The lateral joint line approach studied by 
Wind and coworkers25 was  categorized in the anterolateral approach group. 
In the latter study, the amount of detectable MB during arthroscopy was 
classified as poor, fair or good; procedures classified as ‘good’ by the authors 
were considered accurate.26 The superolateral approach was investigated in 
6 studies (230 knees). Accuracy rates ranged from 70 to 100%10, 20-23, 25 and 
pooled accuracy was 91% (95% CI 84-99%). 
Two studies in the superolateral approach group included patients with 
synovitis21 or clinical effusion.20 The pooled accuracy rate for these studies 
was 98% (95% CI 95-100%). The pooled accuracy rate of the superolateral 
approach group without these studies was 88% (95% CI 77-98%).
The superomedial approach was investigated in the study of Wind and 
coworkers25 and resulted in an accuracy rate of 93%. This was significantly lower 
than the anterolateral approach used in that same study (p=0.001). Accuracy 
rates from the lateral midpatellar approach were examined in two studies 
and resulted in accuracy rates of 76%16 and 93%15, respectively, with a pooled 
accuracy of 85% (95% CI 68-100%). The accuracy of the medial midpatellar 
approach was studied once by Jackson and coworkers16 and resulted in an 
accuracy rate of 56%. This was significantly lower than the investigated lateral 
midpatellar (p<0.0001), the anterolateral (p<0.0001) and the anteromedial 
approach (p<0.0001) in that study. The anterolateral approach was investigated 
in 3 studies.15, 16, 25 Accuracy rates of the anterolateral approach ranged from 
43 to 85% with a pooled accuracy of 67% (95% CI 43-91%). The 43% accuracy 
rate of the anterolateral approach in the study of Wind and coworkers25 was 
significantly lower (p<0.001) than the accuracy rates from the superolateral 
and superomedial approach in the same study. The anteromedial approach 
was also investigated in 3 studies10, 15, 16 and accuracy rates ranged from 62-
73% with a pooled accuracy of 72% (95% CI 65-78%). In the study of Waddell 
and coworkers24, 30o-40o flexion was applied while injecting lateral from the 
patellar tendon, which resulted in a 100% accuracy rate. This approach was 
32 Chapter 2
modified in the study of Toda et el.10, where traction at the ankle joint was 
added while injecting from the medial side in the 30o-40o flexed knee; this 
modified approach resulted in an accuracy rate of 86%.
In 2 studies, the superolateral approach resulted in 100% accuracy in 
patients with synovitis21 or effusion of the knee joint.20 In the study of Wind 
and coworkers25, patients with or without clinical knee effusion were also 
injected in the knee through the superolateral approah. This resulted in an 
89% accuracy rate, whereas the anterolateral approach in this study reached 
a significantly lower accuracy rate of 43% (p<0.001). 
The severity of underlying disease related to accuracy rates of intra-articular 
injections was explored in the study of Toda and coworkers10 Accuracy 
rates of subgroups with different Kellgren and Lawrence (K&L) grade OA 
were presented. In the K&L grade II and III groups, no significant differences 
were found between the superolateral approach, anteromedial approach 
and modified approach by Waddell. In the K&L grade IV group the modified 
approach by Waddell reached 100% accuracy, which was significantly higher 
than the superolateral and anteromedial approach (both 55%, p=0.035).
In 2 studies10, 23 approach-related factors were identified. In the study of Luc 
and coworkers23 A 97% accuracy rate using the superolateral approach was 
reported applying the so-called backflow technique, ie, lidocaine is injected 
(1 mL at a time) until backflow of the injected lidocaine occurs, then contrast 
is injected and radiographs are taken to determine accuracy. In the study of 
Toda and coworkers10 traction at the ankle joint was applied while injecting the 
affected knee joint at the medial side of the patellar tendon. This approach is 
a modification of the approach used in the study of Waddell and coworkers24, 
and the overall accuracy rate was 86% with a 100% accuracy rate in the K&L 
grade IV subgroup.
Most studies did not report any local reactions related to the used 
approach.10, 15, 16, 20, 23-25 In 1 study22 a patient suffered from a quadriceps 
bleeding 1 week after extra-articular needle placement. Another study 
investigated intra-articular injections in several peripheral joints. Hypotrophy 
and/or hypochromia of the skin was found in 10% of the group injected 
extra-articularly compared to 4.7% injected intra-articularly.21
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Figure 2 Approaches of knee injections
Superomedial approach
knee in extension, injection under 
superomedial patella margin
Superolateral approach
knee in extension, injection under 
superolateral patella margin
Medial midpatellar approach
knee in extension, injection medial 
under horizontal patella midline
Lateral midpatellar approach
knee in extension, injection lateral 
under horizontal patella midline
Anteromedial approach
knee in 90o flexion, injection medial from 
patellar tendon towards intercondylar 
notch
Anterolateral approach
knee in 90o flexion, injection lateral from 
patellar tendon towards intercondylar 
notch
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Modified Waddell’s approach
knee in 30o flexion, traction at ankle, 
injection 1-1,5 cm above anteromedial 
injection site towards anterior contact 
point femoral condyle
Waddell’s approach
knee in 30o-40o flexion, injection 
1-1,5 cm proximal from anterolateral 
arthroscopy portal towards anterior 
contact point femoral condyle-tibial 
plateau
all pictures show the left knee
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Table 4 Accuracy results
First author, 
Year of publication
Accuracy percentage per approach (no. of intra-articular needle 
placements/no. of needle placements)
SL SM LMP MMP AL AM WA MWA
Bliddall22, 1999 91  
(51/56)
Esenyel16, 2007 76 
(59/78)
56 
(44/78)
85 
(66/78)
73 
(57/78)
Glattes20, 2004 100 
(10/10)
Jackson15, 2002 93 
(74/80)
71 
(57/80)
75 
(60/80)
Lopes21, 2008 100 
(37/37)
Luc23, 2006 97  
(32/33)
Toda10, 2008* 70  
(35/50)
62 
(31/50)
86 
(43/50)
K&L II 86  
(18/28)
71 
(15/28)
86 
(18/28)
K&L III 61  
(11/18)
56 
(10/18)
78 
(14/18)
K&L IV 55  
(6/11)
55 
(6/11)
100 
(11/11)
Waddell24, 2001 100 
(20/20)
Wind25, 2004** 89 
(39/44) 
93 
(40/43)
43 
(19/44)
Pooled accuracy 
percentage (95% CI)
89  
(84-92)
93  
(81-98)
85  
(78-89)
56  
(45-66)
67  
(43-91)
72  
(65-78)
100  
(84-100)
86  
(74-93)
SL: superolateral approach, leg in extension; SM: superomedial approach, leg in extension; LMP: lateral 
midpatellar approach, leg in extension; MMP: medial midpatellar approach, leg in extension; AL: anterolateral 
approach, leg in 900 flexion; AM: anteromedial approach, leg in 900 flexion;  WA: Waddell’s approach, 
anterolateral with leg in 300-400 flexion; MWA: modified Waddell’s approach, anteromedial with leg in 30o 
flexion and ankle traction towards lateral; K&L: Kellgren and Lawrence scale, *accuracy results also per K&L 
score,**intra-articular staining of injected  methylene blue classified as ‘good’ during arthroscopy.
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Discussion
An accurate intra-articular needle placement in the knee joint is important 
for intra-articular treatment, diagnosis and research purposes of diseases 
such as RA and OA. 
Our systematic review of different approaches for intra-articular needle 
placements such as injections or aspiration in the knee joint revealed that 
the superolateral approach resulted in high accuracy rates10, 20-23, 25, with 
the highest pooled accuracy of 91% (95% CI 84-99%). Furthermore, the 
superolateral approach was studied most (6 studies, 230 knees). Pooled 
accuracy rates for the lateral midpatellar approach, anterolateral approach 
and anteromedial approach were 85% (95% CI 68-100%), 67% (95% CI 43-
91%) and 72% (95% CI 65-78%), respectively. Local reactions related to a 
certain approach are reported occasionally and appear to be related to 
extra-articular needle placement.22, 23
Intra-articular injections or aspiration of knees with effusion are believed 
to be less challenging. In 2 studies in the superolateral approach group 
only patients with synovitis21 or clinical effusion20 were injected in the knee 
joint. Both studies reported 100%20, 21 accuracy. The pooled accuracy rate 
of the superolateral approach group without these 2 latter studies shows 
only a minor difference, i.e. 88% (95% CI 77-98%) compared to the original 
pooled accuracy rate, ie, 91% (95% CI 84-99%). Furthermore, in a third study 
investigating the superolateral approach, patients with knee effusion were not 
explicitly excluded25; these authors reported a significantly higher accuracy 
rate in the superolateral approach group compared to the anterolateral 
approach, ie, 89% and 43%, respectively (p<0.001). This suggests that even 
when effusion could be present, the superolateral approach still results in 
significantly higher accuracy rates.
A contributing factor to lower accuracy rates might be the length of the needle 
used for the procedure. The lowest accuracy rates in the superolateral group 
were reported by Toda and coworkers (70%10) and Wind and coworkers 
(89%25) both using a needle only 1.25 inch long. In the other included studies, 
in the superolateral approach group 1.5 or 2.0 inch needles were used; 
higher accuracy rates (91-100%) were reported using these longer needles.
In a pilot study reported by Jackson and coworkers15 the distance from skin 
edge to femoral condyle was measured by MRI, ranging from 4.4-5.5 cm 
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(1.8-2.2 inches). Looking at the anterolateral approach group, only 1.5-2.0 inch 
needles were used.15, 16, 25 Pooled accuracy rate in this group was 67% (95% 
CI 43-91%) and extra-articular injections were mainly reported in Hoffa’s fat 
pad. This suggests that a needle longer than 2 inches should be used for 
intra-articular injections via the anterolateral approach. 
The results from the study of Toda and coworkers10 suggest that applying 
traction at the ankle during injection can contribute to a high accuracy rate in 
patients with K&L grade IV OA. Toda and coworkers10 reported a significant 
difference in accuracy rate (100%) in the K&L grade IV group in favour of 
the modified approach by Waddell, compared to the superolateral and 
anteromedial approach (both 55%, p=0.035) in which no traction is applied 
during injection. Although only investigated in 1 study, the K&L grade of 
the knee might be important in the choice of injection approach and the 
appliance of traction.
However, in the K&L grade IV subgroup, the clinical implication of the high 
accuracy rate might be less extensive. In treated OA patients, the mechanism 
of HA is reported to be through suppressed cartilage degeneration 26 and 
improved superficial cartilage compactness and thickness.27 However, severe 
OA patients with K&L grade IV show less response to treatment with HA than 
patients with K&L grades I, II or III.4 It is therefore questionable whether HA 
should be used in patients with K&L grade IV OA.
The results of the risk of bias assessment using the QUADAS tool17-19 (Table 
3) show minor differences between the included studies. In assessing pooled 
accuracy rates, the sample size of the included studies is of great importance. 
Although this is a discriminating factor between the included studies in the 
present review, it is not part of the scored items in the QUADAS tool. In our 
review the QUADAS tool did not contribute to an obvious distinction between 
the included studies included.
To our knowledge the present study is the first systematic review of 
the available literature on this topic. The present review shows that the 
superolateral approach resulted in the highest pooled accuracy rate of 91% 
(95% CI 84-99%) and was investigated most in the included articles. The 
lateral midpatellar, anterolateral and anteromedial approach result in lesser 
pooled accuracy rates. Sufficient needle length should be considered before 
performing any intra-articular needle placement procedure in the knee joint.
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Conclusion
We conclude that for a blindly performed intra-articular needle placement in 
the knee joint, the superolateral approach should be the approach of choice. 
Nevertheless, it is shown that the superolateral approach still results in a 
substantial amount of extra-articular needle placements in blindly performed 
procedures. Guidance of intra articular needle placements by the means of 
imaging techniques may enhance the accuracy. The costs and extra time 
associated with the implementation and use of imaging guided procedures 
in daily practice should be taken in consideration. 
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Appendix 1 Used search strategy
Embase
(knee/exp OR ((genu:ti,ab OR knee:ti,ab OR femorotibial: ti,ab OR 
tibiofemoral:ti,ab OR femoral-tibial:ti,ab OR tibial-femoral:ti,ab) AND 
(joint*:ti,ab OR arthros*: ti,ab))) AND (‘intraarticular drug administration’/exp
OR ((intraarticular:ti,ab OR intraarticular:ti,ab) AND (injection*:ti,ab OR 
administration*:ti,ab)) OR ‘needle
placement’:ti,abOR‘needle placements’:ti,ab)NOT(animal* NOT human*).
PubMed
(knee[mesh] OR knee joint[mesh] OR ((genu[tiab] OR knee[tiab] OR 
femorotibial[tiab] OR tibiofemoral[tiab] OR femoral-tibial[tiab] OR tibial-
femoral[tiab]) AND (joint*[tiab] OR arthros*[tiab]))) AND (injections, 
intraarticular[mesh] OR intraarticular injection*[tiab] OR intraarticular 
injection*[tiab] OR (intraarticular[tiab] AND administration[tiab]) OR needle 
placement*[tiab]) NOT (animal*[tw] NOT human*[tw]).
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Abstract
Objective
Although the knee joint is one the most affected joints by osteoarthritis (OA), 
research on economic implications focussed merely on OA in general. The 
goal of this study was to identify and quantify knee-related productivity and 
medical costs in knee OA patients in paid employment. Furthermore, we 
evaluated associations between productivity loss and relevant patient, health 
and work characteristics.
Methods
Consecutive knee OA patients with mild to moderate knee OA who were 18-65 
years of age, had conservative treatment ≥ 6 months and had paid employment 
were included. Productivity loss and health care consumption were measured 
by questionnaires. Associations between productivity loss and patient, health 
and work characteristics were explored with regression analyses.
Results
In total, 117 knee OA patients with a mean age of 53.2 years and a body mass 
index of 28.8 kg/m2 were included. Total knee-related productivity costs and 
medical costs were €871 (median €411, interquartile range (IQR) €107-1200) 
per patient per month, with total productivity costs of €722 (median €217, 
IQR €0-1041) and total medical costs of €149 (median €137, IQR €72-198). 
More pain during activity and performing physically intensive work were 
significantly associated with productivity loss.
Conclusion
The total knee-related productivity costs and medical costs of conservatively 
treated symptomatic knee OA patients with paid employment in The 
Netherlands are €871 per patient per month, with productivity costs accounting 
for 83% and medical costs for 17%. Productivity loss is associated with having 
more pain during activity and performing physically intensive work. Developing 
adequate treatment strategies for knee OA may be cost beneficial.
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Introduction
Osteoarthritis (OA) is a chronic joint disease frequently affecting middle aged 
and older people 1. The prevalence of clinical OA is about 12% in persons 
aged 25-74.2 Due to aging and increasing life expectancy, OA is expected to 
become the worlds fourth leading cause of disability in 2020.3 OA accounts 
for the majority of the economic burden of arthritis, estimated at 1 to 2.5% of 
the gross national product in western countries.4-6
The economic burden of OA consists of productivity and medical costs.7-9 
Productivity costs are subdivided in costs due to lost productivity while 
being present at work10-12, costs due to absence from work13, 14, and costs 
for compensation of household work by others.7 Studies investigating 
musculoskeletal disorders show that the majority of the productivity costs 
are subscribed to lost productivity while being present at work.14-16 Medical 
costs comprehend the costs of all resources consumed in the health care 
sector and patients’ out of pocket expenses.7-9, 17
Productivity costs are influenced by several factors. Patient characteristics 
like increased body mass index (BMI)18-21 and disease characteristics like pain15 
are frequently associated with productivity loss. The same applies to several 
work-related physical factors such as frequently using force22 and bending or 
twisting the upper body.23 Although kneeling, squatting and heavy lifting are 
known for their relation to knee OA24, their associations to productivity loss 
have yet to be determined. Work-related psychosocial factors like low job 
autonomy, high job demands and emotionally demanding work14, 22, 23, 25, 26 are 
furthermore often associated with productivity loss.
The knee joint is one of the joints most frequently affected by OA.27, 28 
Nevertheless, research on the economic implications of joint disease has 
focussed merely on arthritis or OA in general.4, 6, 8, 9, 17, 29-31 The main goal of 
this study was to identify and quantify knee-related productivity and medical 
costs in conservatively treated knee OA patients with paid employment in 
The Netherlands. The secondary goal was to evaluate the associations 
between knee-related productivity loss and individual, disease and work 
characteristics.
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Patients and methods
Study sample
The study subjects participated in a randomised controlled trial (RCT) 
investigating the cost-effectiveness of intra articular hyaluronic acid in 
addition to usual care, registered at the Dutch trial register (www.trialregister.
nl). Inclusion took place between May 2009 and May 2010 in the Erasmus MC 
University Medical Center in Rotterdam (The Netherlands) and the Reinier de 
Graaf Hospital in Delft, The Netherlands. The RCT focussed on patients with 
mild to moderate knee OA receiving conservative treatment and who were 
not scheduled for knee OA-related surgery in the near future. Consecutive 
patients with knee OA consulting an orthopaedic surgeon at the outpatient 
clinic of one of the 2 participating hospitals were included. Patients with a 
Kellgren/Lawrence (K/L) grade of 1-3 and with a minimum numeric rating 
scale (NRS) for pain of 2 were eligible. At the time of inclusion, subjects were 
18-65 years of age and had to be treated conservatively for their knee OA for 
≥ 6 months prior to inclusion. Patients with K/L grade IV or patients scheduled 
for knee OA related surgery within 1 year were not considered eligible for 
participation. The local Medical Ethics Committee approved the study and all 
patients signed an informed consent. For the aim of this study, we performed 
a cross-sectional analysis on patients from abovementioned study sample 
who were involved in a paid employment at the baseline measurement. Only 
data acquired from the baseline measurement and therefore before onset 
of any trial intervention were used.
Productivity and medical costs
The Productivity and Disease Questionnaire (PRODISQ)32 was used for the 
measurement of productivity costs due to knee symptoms. This questionnaire 
covers relevant aspects of the relationship between health and productivity 
including knee-related absence from work during the past 3 months. It 
includes the measurement of lost productivity due to knee symptoms while 
being present at work by the quality and quantity method.11, 32 Subjects are 
asked to rate the quality and quantity of work performed on their last work 
day compared to a regular workday on a 10-point NRS. Zero represents 
no quantity or quality and 10 represents normal quantity or quality. The 
quantity scale was used for the calculations on productivity loss due to 
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the high correlation33 between the both scales. To assess compensational 
mechanisms for productivity loss in the household, subjects were asked to 
indicate the amount of work in the household taken over by others.
Knee-related health care consumption in the prior 3 months was obtained 
through patient questionnaires. This included physician and paramedical 
therapist visits in primary and secondary care, use of aids (braces, inlay soles, 
crutches, etc.), use of home care, and medication use. Medication costs 
included the prescription fees pharmacists receive per prescription.34
Resources were valuated according to Dutch guideline prices and tariffs34 
(Table 1). If no prices were available (e.g. homeopath tariffs), the tariff was 
calculated based on mean tariffs charged by different practices. Tariffs for 
diagnostic imaging were obtained from the 2 participating hospitals. Tariffs for 
mobility aids were obtained from qualified homecare companies specialized 
in mobility aids reimbursed by health insurance companies. The depreciation 
time for sustainable aids like crutches, orthopaedic soles and braces was set 
on 2 years. Costs made solely for the participation of this study were omitted 
from the cost analyses.
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Table 1 Prices used in the productivity and medical costs analyses
Item Costs
Productivity costs (per hour)*
Paid work € 30,02 
Unpaid work € 12,50 
Medical costs (per visit) *
Primary care
Physical therapist € 36,00
General practitioner € 28,00 
Company physician € 62,50 
Other† € 24,00 - 35,00
Secondary care (visit)*
Orthopaedic surgeon € 72,00 
Rheumatologist € 72,00 
Other‡ € 72,00
Medication (per unit)§
Acetaminophen§ € 0,02 
Nonsteroidal antiinflammatory drugs¶ € 0,37 
Glucosamine¶ € 0,28 
Gastro protective agents¶ € 0,50 
Other# € 0,13 - 0,84
Prescription fee € 5,99
Imaging (unit) **
Radiographs € 19,28 
Magnetic resonance imaging € 300,00 
Other†† € 105,89 - 250,00
Aids (unit)¶
Cold/warm compresses € 1,95 
Elastic bandage € 22,50 
Knee braces € 75,00 
Orthopaedic sole € 126,00 
Other‡‡ € 1,50 - 3.200,00
*According to published Dutch guidelines 34 † Price range of sports massage, homeopath, home care, 
practice therapist, and sports physician. Mean price of different practices. ‡ Price range of revalidation 
physician, neurologist, and surgeon. § According to the Health Care Insurance Counsel. ¶ Mean price of 
different products within the same product type. # Price range of aspirin, chondroitin, and nonsteroidal 
antiinflammatory drug gel. Mean price of different products within the same product type. ** Price is based 
on charges from the 2 participating hospitals. †† Price range of ultrasound, scintigraphy, and single-photon–
emission computed tomography. ‡‡ Price range of crutches, tape, walking stick, shower chair, wheel chair, 
and bicycle adaption. 
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Patient, health and work characteristics
Patient characteristics enclosed age, gender, BMI and the level of education. 
Health characteristics included the NRS for pain35 during rest and during 
activity and the presence of concomitant back pain. Quality of life (QOL) was 
assessed by the EuroQol 5-domain questionnaire (EQ-5D)36, 37 resulting in a 
score between 0 (death) and 1 (perfect health). Knee-related function was 
assessed by the Knee injury and Osteoarthritis Outcome Score (KOOS).38, 39 
This questionnaire consists of 5 subscales (pain, other symptoms, functioning 
in activities of daily living (ADL), functioning in sport and recreation and knee-
related QOL). A normalized score was calculated for each subscale, in 
which 100 indicates no symptoms and 0 indicates extreme symptoms. 
Work characteristics were separated into physical and psychosocial factors. 
Physical factors concerned the items known for their relation to knee (regular 
presence of kneeling or squatting, moving heavy loads and performing 
physically intensive work) OA.24 These items were assessed using a 4-point 
scale containing “rarely or never“, “now and then“, “often“ and “always“. The 
latter 2 answers were considered high exposure to the physical factor of 
interest.23, 25
The psychosocial workload was assessed by questions based on the demand 
control support model of Karasek et al.40 This included the dimensions job 
control, skills discretion, work demands and psychosocial work environment. 
Job control questions concerned influence on the planning of work and 
ability to postpone work if necessary. Skills discretion covered variety in 
work, involvement in complex matters and learning new matters. Work 
demands items included insufficient time to complete work, excessive work 
and working overtime. Questions on the psychosocial work environment 
concerned social interaction and loyalty between co-workers, support from 
supervisor in personal development and encouragement from supervisor 
in autonomy of work planning. Four or 5-point scales were used for these 
questions and for each dimension a sum score was calculated. Patients with 
median sum scores or higher were regarded as exposed.23, 41
Statistical analyses
Descriptive statistics were used to describe the study sample characteristics. 
All investigated costs were proportionally converted to costs per month. 
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The associations between quantity of work while being present at work 
and patient, health and work characteristics were explored with univariate 
linear regression analyses. For the exploration of absence from work and 
aforementioned characteristics we used univariate logistic regression 
analysis. Variables reaching a P value less than 0.20 in the univariate model 
were investigated in the multivariate regression model. Age and sex were 
considered potential confounding variables and were included in the 
multivariate regression analyses. A variable was retained in the multivariate 
model when statistically significant at a P value below 0.05. To identify 
interactions, correlations between investigated in the multivariate model 
were explored. If necessary, the model was adjusted for interacting variables. 
Given the size of the study sample, the number of independent variables in 
1 model was limited. Analyses were performed using Statistical Package for 
Social Sciences, version 17.0.42
Results
Study sample
Patient characteristics are presented in Table 2. In total, 117 patients were 
included in this study, of which 50 (43%) were women. The mean age ± SD 
was 53.2 ± 7.4 years, mean ± SD BMI was 28.8 ± 5.1 kg/m2. More than half of 
the sample (n=62, 53%) experienced knee symptoms >12 months at the time 
of inclusion. The mean ± SD NRS score for pain during rest was 4.4 ± 2.6 and 
for pain during activity 6.1 ± 2.4. The KOOS average subscale scores did not 
exceed 58.1 (function in ADL scale). The mean ± SD score on the KOOS pain 
scale was 50.0 ± 20.8). The lowest mean ± SD score was 28.2 ± 25.5) for the 
function in sports and recreation scale.
In total, 47 patients (40%) reported productivity loss (quantity) due to knee 
symptoms, compared to a regular work day. The mean ± SD score on the 
quantity scale was 8.6 ± 2.3, indicating an average productivity loss of 14% 
while being present at work. Twenty-three patients (20%) reported ≥1 
episode of absence from work in the last 3 months due to knee symptoms. 
High exposure to work related physical determinants was present in 14-26 
of the patients (12-22%), of which performing physically intensive work was 
the physical determinant most present (n=26, 22%). High exposure to work 
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related psychosocial determinants were present in 44-52 patients (38-44%), 
of which lack of job control was the psychosocial determinant most present 
(n=52, 44%).
Table 2 Baseline characteristics (n=117)
Individual characteristics
Age, mean ± SD years 53.2 ± 7.4
Female, no.  (%) 50 (43)
BMI mean ± SD kg/m2 28.8 ± 5.1
Education, no. (%)
Lower level 13 (11)
Intermediate level 70 (60)
Higher level 34 (29)
Job type, no. (%)
Agriculture 4 (3.4)
Industry 14 (12.0)
Commercial services 61 (52.1)
Non-commercial services 30 (25.6)
Government 8 (6.8)
Health related characteristics
Duration knee symptoms for 3-12 months,  no. (%) 55 (47)
Duration knee symptoms  for 12 months,  no. (%) 62 (53)
NRS knee pain during rest (0-10), mean (sd) 4.4 ± 2.6
NRS knee pain during activity (0-10), mean (sd) 6.1 ± 2.4
Concomitant back pain, n (%) 35 (30)
K/L  grade, no. (%)
1 10 (9)
2 58 (49)
3 49 (42)
Quality of life, EQ-5D (range 0-1), mean ± SD 0.70 ± 0.23
KOOS  subscales range (0-100), mean ± SD†
Pain 50.0 ± 20.8
Other symptoms 58.0 ± 20.1
Function in activities of daily living 58.1 ± 22.2
Function sports and recreation 28.2 ± 25.5
Knee-related quality of life 33.3 ± 18.6
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Work related characteristics
Hours per week, mean ± SD 31.8 ± 11.7
Hindrance in work due to knee complaints, no. (%) 94 (80)
Quantity (range 0-10) due to knee complaints, mean ± SD 8.6 ± 2.3
Quality (range 0-10) due to knee complaints, mean ± SD 9.3 ± 1.6
Absence in the past 3 months due to knee symptoms, no. (%) 23 (20)
Physical factors, no.(%)
Prolonged kneeling or squatting 17 (15)
Moving heavy loads >25 kg often 14 (12)
Performing physically intensive work 26 (22)
Psychosocial factors,  no. (%)
Lack of job control 52 (44)
Poor skills discretion 46 (39)
High work demands 44 (38) 
Poor psychosocial environment‡ 46 (41)
* BMI=body mass index; NRS=numerical rating scale; K/L=Kellgren/Lawrence; EQ-5D= EuroQol 5-domain 
questionnaire; KOOS=Knee injury and Osteoarthritis Outcome Score; NRS=Numeric Rating Scale. † N = 116 
in the subscales function of all day life, function in sports and recreation and knee-related quality of life. 
‡ N= 113, item includes relation to supervisor, 4 patient without supervisor
Productivity costs and medical costs
The prices used for the cost analyses are listed in Table 1. The average 
total monthly knee-related productivity costs were €722 (median €217, 
interquartile range (IQR) €0 - 1041) per patient per month. Knee-related lost 
productivity while being present at work accounted for the largest part of 
productivity loss (14.9 hours). The costs associated with this productivity loss 
were €448 per patient per month (median €0, IQR €0 -608) and accounted 
for 62% of the total productivity costs. Knee-related absence from work was 
responsible for 6.6 hours, corresponding to €197 (median €0, IQR  €0 - 0). 
Compensation for work in the household was responsible for 6.2 hours and 
€77 (median €0, IQR  €0 - 54).
The average total knee-related medical costs were €149 (median €137, IQR 
€72 - 198) per patient per month (Table 3). In primary care, the physical 
therapist and general practitioner were visited most frequent with on 
average 1.37 and 0.28 visits per patient per month, respectively. The mean 
total costs for primary care comprised €62 (median €31, IQR€9 - 96) per 
patient per month, being the main component of the total medical costs. 
In secondary care, the orthopaedic surgeon was visited on average 0.42 
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times per patient per month. The mean total costs for secondary care were 
€33 (median €24, IQR€24 - 48) per patient per month. Acetaminophen and 
nonsteroidal antiinflammatory drugs were the most used medications, with 
an average use of 14.95 and 11.73 units per patient per month, respectively. 
The average amount of glucosamine taken was 3.59 tablets per patient per 
month. The mean medication costs were €8 (median €0, IQR €0 - 13) per 
patient per month. Most aids most often used were compresses, bandages, 
braces and orthopaedic soles, with 39, 34, 26 and 22 patients using these 
aids in the last month. The mean total costs for aids were €6 (median €2, IQR 
€2 - 5) per patient per month. On average, patients underwent 1.29 x-rays for 
their knee symptoms per month. The mean total costs for diagnostic imaging 
were €40 (median €26, IQR €19 - €40) per patient per month.
The mean total of productivity costs and medical costs was €871 (median 
€411, IQR €107 - 1200) per patient per month. Figure 1 shows the productivity 
costs and medical costs for each subject in the study. Productivity costs 
accounted for €722 (median €217, IQR €0 - 1041), corresponding to 83% of 
the total costs, and medical cost accounted for €149 (median €137, IQR €72 
- 198) corresponding to 17% of the total costs.
Figure 1 Productivity costs and medical costs for individual subjects
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Associations with productivity loss
Loss of productivity due to knee symptoms was measured with the quantity 
scale (correlation quality scale Pearson’s r=0.66). Univariate regression 
analyses (Table 4) showed that a higher BMI was significantly associated with 
lower quantity while being present at work. Furthermore, more pain during 
rest as well as during activity and QOL were significantly associated with 
lower quantity on a regular work day. Of the work characteristics, performing 
physically intensive work, poor skills discretion and a poor psychosocial work 
environment was significantly associated with lower quantity of work. In the 
multivariate linear regression model, only pain during activity (b -0.28 (95% 
confidence interval (95% CI) -0.47, -0.09) and performing physically intensive 
work (b -1.73, (95% CI -2.62, -0.84) showed significant associations with lower 
quantity of work.
A higher BMI was significant associated with absence from work due to 
knee symptoms (Table 5). Furthermore, more pain during rest and during 
activity and lower QOL resulted in significant associations with absence from 
work. Within the work characteristics, physical factors like moving heavy 
loads often and performing physically intensive work were significantly 
associated with absence from work. Of the psychosocial factors, lack of job 
control, poor skills discretion and high work demands were all significantly 
associated with absence from work. Due to mutual correlations between the 
work characteristics, we included the variables with the strongest univariate 
association (BMI and QOL) in the multivariate model. Age and gender were 
thus not corrected for. Significant work characteristics were then added 
separately to the model. This resulted in a significant independent association 
from performing physically intensive work with absence from work (adjusted 
odds ratio 4.2 (95% CI 1.48 - 11.93)).
Overall, having more pain during activity and performing physically intensive 
work are associated with productivity loss. In the multivariate analysis, other 
patient, health or work characteristics did not contribute significantly and when 
added to the final models the regression coefficients remained unchanged.
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Table 4 Univariate and multivariate linear regression analysis and 95% CIs for quantity while 
being present at work (n=117)*
Univariate analyses Multivariate analyses
b (95% CI) b 95% CI†
Individual characteristics
Age -0.04 (-0.10,  0.02)‡
Gender (man->vrouw) -0.36 (-1.21, 0.49)
BMI -0.07 (-0.16, 0.01)‡
Health characteristics
NRSa knee pain during rest -0.33 (-0.48, -0.17)‡
NRSa knee pain during activity -0.39 (-0.55, -0.23)‡ -0.28 (-0.47, -0.09)§
Concomitant back pain -0.34 (-1.35, 0.68)
Quality of life (EQ-5D)  3.28  (1.57, 4.99)‡
Work characteristics
Physical factors
Prolonged kneeling or squatting -0.30 (-1.49, 0.90)
Moving heavy loads (>25kg) often -0.28 (-1.58, 1.02)
Performing physically intensive work -1.92 (-2.87, -0.97)‡ -1.73 (-2.62, -0.84)§
Psychosocial factors
Lack of job control -0.37 (-1.21, 0.48)
Poor skills discretion -0.93 (-1.78, -0.08)‡
High work demands -0.17 (-1.04, 0.70)
Poor psychosocial work environment -0.73 (-1.60, 0.14)‡
* 95% CI=95% confidence interval; BMI= body mass index; NRS=numerical rating scale; EQ-5D=EuroQol 
5-domain questionnaire. † Adjusted for age and sex. ‡ Significant at P <0.20. § Significant at P <0.05.
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Table 5 Univariate and multivariate logistic regression analysis and 95% CIs for sickness 
absence (n=117)*
Univariate analyses Multivariate analysesb
OR (95% CI) OR (95% CI)†
Individual characteristics
Age 1.04 (0.97   -   1.11)
Gender 0.77 (0.31   -   1.93)
BMI 1.12 (1.03   -   1.22)‡
Health characteristics
NRS knee pain in rest 1.17 (0.98   -   1.41)‡
NRS knee pain during activity 1.17 (0.94   -   1.44)‡
Concomitant back pain 0.46 (0.13   -   1.70)
Quality of life (EQ-5D) 0.23 (0.04   -   1.32)‡
Work characteristics
Physical factors
Prolonged kneeling or squatting 1.90 (0.59   -   6.06)
Moving heavy loads (>25kg) often 3.80 (1.17   -   12.34)‡
Performing physically intensive work 3.75 (1.40   -   3.04) ‡ 4.20 (1.48  -  11.93)§
Psychosocial factors
Lack of job control 1.83 (0.73   -   4.60)‡
Poor skills discretion 2.40 (0.95   -   6.07)‡
High work demands 2.11 (0.84   -   5.32)‡
Poor psychosocial work environment 1.80 (0.71   -   4.52)
* 95% CI=95% confidence interval; BMI= body mass index; NRS=numerical rating scale; EQ-5D=EuroQol 
5-domain questionnaire. † Adjusted for age and sex. ‡ Significant at P <0.20. § Significant at P <0.05.
Discussion
In this study we investigated the productivity and medical costs due to knee 
symptoms in conservatively treated knee OA patients in paid employment. 
The productivity and medical costs of knee OA have been investigated once 
in a retrospective study examining 254 patients in Italy by Leardini et al.43 In 
this study, 27% of the costs were medical costs and 73% were productivity 
costs. In our study, 17% medical costs and 83% productivity costs were 
reported. The difference in the cost ratios can be explained by the age 
and employment level of both study samples. The mean age in the study 
of Leardini was 65.8 years and 21.3% had paid employment. In our study 
the mean age was 52.3 years and 100% had paid employment; therefore 
the contribution of productivity costs is higher due to our restriction to a 
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working population. The difference in medical costs could be subscribed to 
the inclusion of conservatively treated patients as well as surgically treated 
patients and the inclusion of patients with K/L grade 4 (10,3%). These findings 
suggest higher disease severity in the population of Leardini, explaining the 
rise of medical costs.3, 44
Another study of Rabenda et al investigated direct (medical) and indirect 
(productivity) costs of OA in a large community-based population in Belgium9. 
Productivity loss due to knee OA related absence from work was reported to 
be 0.8 sick days per patient per month. In our study we found an average of 
6.6 hours absence per patient per month, which is similar to approximately 
0.8 days, based on an 8-hour work day. Productivity costs due to productivity 
loss while being present at work were not accounted for in the study of 
Rabenda et al. Still, these costs predominated the medical costs, which is in 
line with the results of our study. 
Our findings are in concordance with the results of other studies investigating 
musculoskeletal disorders.13-16, 30 Productivity costs in these studies are also 
reported to exceed medical costs and the magnitude of the productivity 
costs was mainly driven by costs due to decreased productivity while being 
present at work.14-16
It must be noted that this cross-sectional investigation of productivity and 
medical costs due to knee OA has some limitations. The sample size of 
our study is 117 patients. This sample was recruited from a population of 
knee OA patients participating in a RCT investigating the cost-effectiveness 
of intraarticular hyaluronic acid in addition to usual care. Patients were 
screened for eligibility and asked to participate in the RCT after visiting the 
orthopaedic outpatient clinic of one of the 2 participating hospitals.  For 
the aim of this particular study, we performed a cross-sectional analysis on 
the baseline data of patients from the abovementioned RCT who had paid 
employment at the moment of inclusion. Due to the sample size, this study 
has a limited discriminatory power to identify all relevant determinants of 
productivity loss.
The aforementioned community based study of Rabenda9 investigated 617 
OA patients who were employed. Another study investigating the economic 
impact of OA-related pain included 2173 patients who were employed.44 
Although these studies present larger samples, the prevalence of OA was 
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self-reported and only assessed through questionnaires. In our study we 
included patients with clinical as well as radiological confirmed knee OA by 
a physician. Also, we collected data on a more detailed level compared to 
these 2 larger studies. This ensured us to perform a complete survey of 
the productivity costs and medical costs in OA patients in paid employment 
seeking medical treatment in a hospital.
Our study sample consists of patients consulting an orthopaedic surgeon for 
their knee symptoms and comprised secondary care patients only. It must be 
noted that this is a selected sample within the whole population of patients 
with knee OA. We stress the fact that our study results represent the medical 
and productivity costs of a conservatively treated group of working people 
with mild to moderate knee OA who are treated in secondary care. Mild to 
moderate knee OA was defined by our criteria of radiological knee OA with K/L 
grade of 1-3 and a minimum score on the NRS for pain of 2. Including patients 
with less severity of clinical or radiological knee OA would probably have led to 
lower productivity and medical costs. Also, including patients from a primary 
care setting could have led to cost differences, possibly due to differences in 
disease severity and management strategies compared to secondary care. 
Furthermore, previous research shows that medical and productivity costs 
are higher in patients experiencing pain due to arthritis.15, 45 Since the course 
of OA is characterized with intermittent periods of pain increase, it is plausible 
that measuring over a longer time span would have included periods in which 
patients experienced less pain. Therefore, an overestimation of productivity 
and medical costs cannot be excluded in our study. 
The total productivity costs are attributable to only 47% of the study sample, 
resulting in a difference between mean total productivity costs (€722) and 
median total productivity costs (€217). The medical costs were also not 
evenly distributed between study subjects (Table 3), although some medical 
costs were reported by all but 1 subject. Skewness of the distribution of 
productivity costs as well as medical costs is a phenomenon regularly seen 
in studies investigating costs in musculoskeletal and non-musculoskeletal 
disorders.46-50 In these studies, the majority of the productivity costs were 
also attributable to a limited part of the study sample.
Comparing the patients reporting any productivity loss to the patients not 
reporting productivity loss shows several differences. Patients indicating 
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knee-related productivity loss have a higher mean BMI and report higher 
mean pain scores compared to patients not reporting any productivity loss. 
Furthermore, lower scores on all KOOS function scales and on the quality 
of life scale are reported by this group. Finally, the presence of all physical 
and psychosocial work factors was higher in the group reporting productivity 
loss compared to the group not reporting productivity loss. Ultimately, these 
differences resulted in a statistical significant relation between performing 
physically intensive work and having more pain during activity with productivity 
loss in the multivariate regression model.
Research on precision and accuracy in measuring absence from work in 
calculating productivity costs in The Netherlands reported a very good accuracy 
of a recall period of 2 months, which decreases considerably when applying 
a recall period of 6 months.51 In our study, absence from work was the only 
item assessed with a recall period >2 months (3 months). As this recall period 
of 3 months is quite close to 2 months, we expect the recall bias to be limited. 
Nevertheless, there is possibility that the amount of productivity costs due 
to absence from work was subject to underestimation. It is possible that the 
amount of productivity costs due to absence from work was underestimated.
In this investigation we presented an overview of the medical costs in patients 
with knee OA. Some out-of-pocket expenses like parking tickets and gasoline 
made for transfers to the hospital were not accounted for in the calculation 
of the medical costs. This could be compensated for by the fact that some 
patients visited a resident in orthopaedic surgery instead of the orthopaedic 
surgeon. In our costs calculations, we only used the specialist tariff.
The present study shows that the total of knee-related productivity and medical 
costs for knee OA patients on average is €871 (median €411, IQR €107 - 1200) 
per patient per month, of which productivity costs account for 83% (€722, 
median €217, IQR €0 - 1041) and medical costs account for 17% (€149, median 
€137, IQR €72 - 198). It also shows that reduced productivity while being present 
at work is responsible for the majority (62%) of the productivity costs. More 
pain during activity and performing physically intensive work were significantly 
related to productivity loss. The monthly costs of knee OA are substantial, 
illustrating the necessity of developing adequate treatment strategies whereby 
intensive treatment regimens for knee OA may be cost-beneficial.
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Abstract
Background
High molecular weight (HMW) hyaluronic acid (HA) is a treatment option for 
knee osteoarthritis (OA). The efficacy of HMW-HA in knee OA is investigated 
extensively, but the effectiveness in patients in the working age is unknown. 
Nevertheless, the number knee OA patients in the working age is increasing. 
Surgical treatment options are less eligible in these patients and productivity 
losses are high. In this study the effectiveness of intra-articular HMW-HA 
added to regular non-surgical usual care in everyday clinical practice (UC) 
compared to UC over 52 weeks in symptomatic knee OA patients in the 
working age was investigated.
Methods
In this open labelled randomized controlled trial, subjects aged between 
18 and 65 years with symptomatic knee OA (Kellgren and Lawrence I-III) 
were enrolled and randomized to UC + 3 weekly injections with HMW-HA 
(intervention) or UC only (control). The primary outcome was the between 
group difference in responders to therapy according to OMERACT-OARSI 
criteria after 52 weeks. These criteria include the domains pain, knee related 
function and patient’s global assessment (PGA). Function was evaluated 
with the KOOS questionnaire. Pain was assessed with the Numeric Rating 
Scale. Secondary outcome comprised the between group difference on the 
individual responder domains, as analysed with a random effects model. 
Odds Ratios (OR) were calculated by logistic regression analysis. Sensitivity 
analyses were performed. 
Results
In total, 156 subjects were included (intervention group 77, control group 
79). Subjects in the intervention group (HMW-HA+UC) were more often 
responder compared to the controls (UC). Depending on whether pain during 
rest or pain during activity was included in the responder domains, 57.1% 
versus 34.2% (p=0.006) and 54.5% versus 34.2% (p=0.015) was responder to 
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therapy respectively. The results of the secondary outcome analyses show 
that scores on individual responder domains over all follow-up moments 
were statistically significant in favour of the intervention group in the domains 
pain during rest (δ 0.8, 95%CI 0.2; 1.4, p=0.010), knee related function (δ -6.8, 
95%CI -11.9; -1.7, p=0.010) and PGA (δ -0.7, 95%CI -0.9; -0.4, p<0.0001). 
Conclusions
Intra-articular HMW-HA added to usual care is effective for knee OA in 
patients in the working age.
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Background
Knee osteoarthritis (OA) is a chronic degenerative disease of the knee joint, 
causing pain, joint stiffness and functional impairment.1-3 The lifetime risk on 
symptomatic knee OA is over 40%.4 Next to health impairment and disability, 
knee OA is associated with substantial healthcare consumption and costs.1, 5, 6
The initial pharmacological treatment for patients with symptomatic knee 
OA generally includes rapid-acting pain medication like acetaminophen or 
non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs have shown to be 
effective in pain reduction and functional improvement in the symptomatic 
treatment of knee OA.7-9 
Treatment with NSAIDs is related to an increased risk of serious gastrointestinal 
and cardiovascular side effects, indicating limited use of NSAIDs only.10, 11 The 
safety profile of NSAIDs contradicts with the chronic character of knee OA in 
which prolonged symptomatic treatment is often required. Additionally, non-
pharmacological interventions such as strength training, exercise and weight 
management are added to the treatment regime.12-14
An alternative treatment for knee OA patients is intra-articular injection 
therapy with hyaluronic acid (HA) 15. Intra-articular HA results in similar effects 
on pain reduction and improvement of function compared to NSAID use, 
without the aforementioned side effects.8, 16, 17 The efficacy of intra-articular 
HA has been investigated extensively in randomized controlled trials (RCTs) 
and subsequently in various systematic reviews and meta-analyses.14, 15 Peak 
effectiveness of a series of intra-articular HA is reached between 1 and 2 
months and residual effects exist up to 6 months.15, 16, 18
Limiting the results of meta-analyses to high quality trials only, the effect on pain 
is still clinically relevant in favour of intra-articular HA.14, 18 There is increasing 
evidence that within the spectrum of available HA derivatives the efficacy of 
HA products with a high molecular weight (HMW) is superior to the efficacy of 
derivatives with a low molecular weight.19, 20
The effectiveness of HMW-HA in knee OA patients in the working age has 
not been evaluated yet. Relevance lies in the fact that the number patients 
with knee OA in the working age is increasing and surgical treatment options 
like unicompartmental or total knee arthroplasty (TKA) are less eligible in 
these patients, especially when they are involved in a physically demanding 
occupation.21, 22 The revision rate of knee arthroplasty in these patients is high 
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and the life span of the prosthesis is limited.23 Furthermore, the costs from loss 
of productivity at work due to symptomatic knee OA are high in patients in the 
working age.24 In this population, the availability of an effective local therapy in 
everyday clinical care could thus offer important healthcare benefits next to 
possible economic benefits.
The aim of this study was to assess the effectiveness of intra-articular HMW-
HA added to usual care (UC) compared to UC over a period of 52 weeks in 
symptomatic knee OA patients in the working age. We hypothesized that adding 
HMW-HA in patients with knee OA has a clinical relevant effect. 
Alongside this effectiveness analysis, a parallel economic evaluation was 
performed which was published previously.25 In this article we report that 
adding HMW-HA to the usual care results in an increase in quality of life. The 
increase is accompanied with an increase in costs. Ultimately this leads to a 
cost-effectiveness ratio of €9.100/ quality adjusted life years (QALY). Given the 
maximum willingness to pay for similar conditions to knee OA we conclude 
that intra-articular HMW-HA added to usual care for knee OA is probably cost-
effective in the treatment of knee OA.
Methods
The current effectiveness evaluation and the previously published cost-
effectiveness evaluation are both part of the VIScosupplementation for Knee 
osteoarthritis (VISK) study. The VISK study is registered at the Dutch trial 
register (www.trialregister.nl, NTR1651). The study protocol is available from the 
corresponding author on request. 
The VISK study does not include a placebo group. In light of the evidence on the 
efficacy of HMW-HA in knee OA, we specifically sought to investigate the actual 
effectiveness of this intervention. Such a study design, in which the intervention 
is compared to what is considered regular care that is provided in an everyday 
clinical setting (without a placebo), is required to facilitate the parallel economic 
evaluation of the VISK study.26, 27
Study sample
Inclusion of eligible subjects took place between May 2009 and May 2010 in 2 
hospitals (1 academic, 1 non-academic) in The Netherlands. Consecutive knee 
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OA patients at the outpatient orthopaedic department meeting the inclusion 
criteria were considered eligible. Patient’s age was set between 18 and 65 years, 
the latter being the pensionable age in The Netherlands at the inclusion period. 
Inclusion criteria were: pain >3 months, mean pain severity ≥2 on the numeric 
rating scale (NRS), Kellgren & Lawrence (K&L) grade I to III in medial and/or 
lateral compartment.
Exclusion criteria were: intra-articular HA injections <1 year, intra-articular 
steroid injection <3 months, arthroscopy <6 months, tibial osteotomy <1 year, 
synovectomy, scheduled knee surgery <1 year, varus/valgus deformity >12 
degrees, chondrocalcinosis, dermatologic knee disorders, allergy to HMW-HA 
components, (planned) pregnancy or lactation, inflammatory arthritis, severe 
hip OA, non-knee related regular analgesic use, daily oral steroid therapy, poor 
general health, conditions interfering with functional assessments, alcoholism, 
patients unable to attend follow-up and insufficient command of the Dutch 
language.
Sample size, randomization and masking
The sample size was calculated to detect a between group difference of 20% 
in the primary outcome parameter which was defined as response to therapy 
at 52 weeks according to OMERACT-OARSI criteria.28 A power of 80% and an 
alpha of 0.05 resulted in a required sample size of 64 subjects per group (128 
subjects in total). Anticipating a 20% dropout over 52 weeks, the final required 
sample size was set at 154 subjects.
Randomization took place after informed consent was signed. Concealed 
randomization was performed by computer generated lists with randomly 
assigned blocs of 2, 4, 6, 8 or 10 subjects. An independent employee not involved 
in any other part of the study performed the randomization. Stratification took 
place for radiologic degree of knee AO (K&L grade I/II versus grade III) and per 
orthopedic surgeons responsible for injections (2 per hospital, 4 in total).
The statistician and investigator responsible for assessment and analyses of the 
data were blinded for the treatment allocation. Due to the study design included 
subjects and orthopedic surgeons administering the study intervention could 
not be blinded. 
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Interventions
Subjects in the intervention group received 3 weekly intra-articular injections 
with Hylan G-F 20 (Sanofi S.A, Paris, France) added to usual care or usual care 
only. Hylan G-F 20 is the HMW-HA derivative with the highest molecular weight 
available for clinical use (6000 kiloDalton. The injections were performed 
through the superolateral approach.29 Usual care was defined accordingly to the 
guidelines on the treatment of knee OA of the Dutch Orthopedic Association. 
This guideline recommends several non-surgical treatment modalities including 
pain medication (eg acetaminophen or NSAIDs), physical therapy and lifestyle 
recommendations.12 Treating physicians were encouraged to follow these 
guidelines, but no treatment restraints were imposed. Other treatments 
were allowed when deemed appropriate in order to maintain the pragmatic 
character of the trial.
Questionnaires
The follow-up was 52 weeks and data was collected through questionnaires by 
mail at baseline, 6, 13, 26, 39 and 52 weeks. Knee related function was assessed 
by the functioning in daily living scale of the Knee injury and Osteoarthritis 
Outcome Score (KOOS).30, 31 A normalized score from 0 (extreme symptoms) to 
100 (no symptoms) was calculated for this subscale. Pain during rest and pain 
during activity was evaluated by the NRS, resulting in a score between 0 (no pain) 
and 10 (most severe pain).32 Patient’s global assessment (PGA) was assessed on 
a 5-point Likert scale on which subjects indicate the amount of improvement of 
their knee complaints compared to baseline (1. fair improvement, 2. moderate 
improvement, 3. no change, 4. moderate deterioration, 5. fair deterioration). 
Medication use and patient reported adverse events were monitored at all 
follow-up moments.
Outcomes
The primary outcome was defined as response to therapy at 52 weeks 
follow-up according to OMERACT-OARSI criteria. This variable presents the 
results of changes after treatment in three symptomatic domains (pain, 
function, and PGA) as a single variable.28 Response to therapy according to 
the OMERACT-OARSI criteria is defined as ≥10% absolute improvement and 
≥20% overall improvement at final follow-up in at least 2 of the 3 responder 
72 Chapter 4
domains (pain, function and/or PGA); or ≥20% absolute improvement and 
≥50% overall improvement in either the pain or function domain. 
The secondary outcome comprised the between group difference over 
the whole follow-up period of the 3 individual primary outcome responder 
domains: pain, function, and PGA.
Statistical analyses
For the primary outcome, the difference in percentage of responders 
according to OMERACT-OARSI criteria between study groups after 52 weeks 
follow-up was calculated.28 In the base case analyses two responder sets 
were investigated: 1. with pain during rest was included in the responder 
domains, next to function and PGA; and 2. with pain during activity included.  
In order to minimize bias in favor of the intervention group, drop-outs and 
subjects lost to follow up were (regardless of their study results) considered 
non-responders in the intervention group, and (vice versa) responders in the 
control group in the final analyses.
Logistic regression analysis with responder as dependent variable and the 
intervention as independent variable were performed to calculate odds 
ratios (OR) including 95% confidence intervals (95%CI) after 52 weeks follow-
up. The number needed to treat (NNT) to attain 1 responder was calculated 
(PASW statistics 17.0).
For the secondary outcome, scores on individual responder domains (pain 
during rest, pain during activity, knee related functioning in daily life, PGA) 
were analyzed over all follow-up moments by means of a random effects 
model with random intercept and slope. The baseline values of the variables 
and the treatment group were included in the model. In this way we obtained 
for each outcome an estimate for the between group difference in score on 
the relevant questionnaires (KOOS, NRS, Likert scale) over the whole follow-up 
period, including associated 95% CI (SAS 9.2, SAS Company).
Sixteen subjects divided over both study groups received knee related 
surgery during follow-up. This number was not foreseen and we therefore 
performed 2 additional sensitivity analyses to assess possible beneficial 
clinical effects on pain and function as a result of the surgery. These analyses 
were not specified in the VISK study protocol a priori. In these sensitivity 
analyses, subject receiving knee related were considered non-responder 
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irrespective of their study results.33 In the first additional analysis, subjects 
who received major knee related surgery (e.g. knee prosthesis implantation, 
high tibial osteotomy) during follow-up were considered non-responders. In 
the second additional analysis subjects receiving any knee surgery (major 
knee surgery plus minor knee surgery like arthroscopy or knee manipulation 
under general anesthesia) were considered non-responders (PASW 
statistics 17.0). All analyses were performed according to the intention to 
treat principle. In order to generate unbiased estimates of the difference 
in effectiveness parameters across both treatment groups, we adjusted for 
baseline imbalances in and, if necessary, for unbalanced covariates. 
Results
Study population 
In total, 156 patients were included of which 77 subjects (mean age 53.6, 
standard deviation (SD) 8.6, range 20.9-64.6) in the intervention group and 
79 subjects (mean age 54.8, SD 6.4, range 32.9-64.9) in the control group. The 
study flowchart is shown in Figure 1. Additional characteristics of included 
subjects are shown in Table 1. One subject in the intervention group received 
only 1 out of 3 planned injections with HA due to a painful first injection and 1 
subject refused the injections of HMW-HA after allocation to the intervention 
group. In the control group, 3 subjects were not motivated for further study 
participation after baseline measurements and randomization, and 1 subject 
was lost to follow-up. All subjects were retained in the analyses of their 
randomization groups. We adjusted for the baseline imbalances on pain and 
functioning in all analyses.
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Figure 1 Flowchart
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Table 1 Population characteristics (n=156)
intervention (n=77) control (n=79)
Mean age, years (sd, range) 53.6 (8.6, 20.9-64.6) 54.8 (6,4, 32.9-64.9)
Female, n (%) 37 (48) 40 (51)
BMI, kg/m2 mean (sd, range) 28.9 (5.2, 20.4-44.8) 29.2 (5.4, 19.4-43.5)
K&L I-II, n (%) 44 (57) 47 (59)
K&L III, n (%) 33 (43) 32 (41)
Duration knee complaints 3-12M, n (%) 34 (44) 43 (54)
Duration knee complaints >12M, n (%) 43 (56) 36 (46)
Pain during rest (0-10) 1, mean (sd, range) 4.8 (2.5, 0-8.0) 4.1 (2.6, 0-10)
Pain during activity (0-10) 1, mean (sd, range) 6.5 (2.4, 0-10) 5.8 (2.4, 0-10)
Quality of life (0-1)2, mean (sd, range) 0.68 (0.23, -0.05-1) 0.71 (0.24, -0.11-1)
KOOS subscales (0-100), mean (sd, range)
Pain 46.6 (20.6, 5.6-100) 52.5 (21.1, 11.1-100)
Other symptoms 55.7 (18.3, 17.9-100) 61.3 (21.8, 3.6-100)
Function in daily life 53.2 (20.2, 7.4-100) 60.2 (24.0, 10.3-100)
Function in sports & recreation 24.0 (25.7, 0-95.0) 31.1 (30.9, 0-100)
Knee related quality of life 30.8 (18.5, 0-68.8) 35.9 (18.7, 0-81.3)
1on Numeric Rating Scale, 2on EQ-5D questionnaire, K&L: Kellgren&Lawrence scale 
Primary outcome
In Table 2 the results on the primary outcome and the results of the sensitivity 
analyses are shown. Subjects in the intervention group were statistically 
significant more often responder to treatment arm they were randomized 
to compared to the control group. When pain during rest was included in 
the responder domains, 57.1% of the subjects in the intervention group 
were responder to therapy, against 34.2% in the control group (p=0.006). 
With pain during activity included, 54.5% of the subjects was responders to 
therapy in the intervention group versus 34.2% of the controls (p=0.015). 
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Table 2 Percentage responders at 52 weeks follow-up (n=156)
Intervention (n=77) Control (n=79) NNT OR (95% CI) p
All subjects analysed
Responder set 1a 57.1% 34.2% 4.4 2.6 (1.3; 4.9) 0.006
Responder set 2b 54.5% 34.2% 4.9 2.3 (1.2; 4.4) 0.015
1st additional analysisc
Responder set 1a 50.6% 31.6% 5.3 2.2 (1.2; 4.3) 0.022
Responder set 2b 48.1% 32.9% 6.6 1.9 (1.0; 3.6) 0.072
2nd additional analysisd
Responder set 1a 50.6% 31.6% 5.3 2.2 (1.2; 4.3) 0.022
Responder set 2b 48.1% 31.6% 6.1 2.0 (1.0; 3.8) 0.049
aPain during rest included in responder domains next to function and PGA , bPain during activity included 
in responder domains next to function and PGA, cSubjects receiving major knee related surgery considered 
non-responder, dSubjects receiving any knee related surgery considered non-responder, OR: Odds ratio, CI: 
confidence interval, NNT: number needed to treat.
Secondary outcome
Over the whole follow-up period, we found statistically significant better 
scores in the intervention group in the domains pain during rest, knee 
related function, and PGA (Figures 2, 3 and 4). These results where statistically 
significant for pain during rest (δ 0.8, 95%CI 0.2; 1.4, p=0.010), knee related 
function (δ − 6.8, 95%CI -11.9; − 1.7, p=0.010) and PGA (δ − 0.7, 95%CI -0.9; − 
0.4, p<0.0001). The intervention group also scored lower on the pain during 
activity score, but this difference was not statistically significant (δ 0.6, 95%CI 
0; 1.2, p=0.060).
Sensitivity analyses
Nine surgical procedures related to the study knee were performed in the 
intervention group during follow-up, versus 7 in the control group. Despite a 
slight decrease in the between group differences in responder percentages, 
the results of both additional analyses are still statistically significant in favour 
of the intervention group (Table 2). 
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Figure 2 Results pain during rest and during activity
Figure 3 Results knee function
Medication use
At baseline, more subjects used pain medication because of knee complaints 
in the intervention group with (53%) compared to the control group (42%). This 
difference decreased over time, resulting in similar usage of pain medication 
for both groups at final follow-up. The difference in pain medication users 
was not statistically significant on any of the time points during follow-up. 
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Figure 4 Results patients’ global assessment 
Adverse events
In the intervention group, more subjects reported knee treatment related 
adverse events (AE) at 6 weeks (45% versus 18%), This difference was mainly 
due to flares or flare like symptoms of the study knee in this period (36% 
versus 10%, p>0.001, number needed to harm (NNH) 4.0). The difference 
decreased at 13 weeks, and at 26 weeks the percentage of subjects reporting 
flares was similar in both groups. None of the between group differences on 
the following time points after 6 weeks were statistically significant. No septic 
arthritis of the study knee occurred in any of the subjects during follow-up.
The amount of non-treatment related AEs was similar in both groups during 
follow-up. An additional file shows the percentage of patients experiencing 
treatment and non-treatment related adverse events per study group per 
time point during study follow-up (Additional file 1).
Discussion
This study is the first to investigate the effectiveness of HMW-HA added to 
usual care in subjects with clinical knee OA in the working age. We showed 
that adding intra-articular injections with a HMW-HA derivative to usual care 
treatment in an everyday clinical setting resulted in statistically significant 
more responders to therapy. It resulted in improvement of pain, function 
and PGA in these patients. The between group difference on 3 out of 4 of 
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the individual responder domains (pain during rest, pain during activity, 
knee related function, PGA) was statistically significant and in favour of the 
intervention group. Subjects in the intervention group experienced more 
episodes of transient knee pain and/or swelling during the first 6 weeks.
In our study we specifically choose to include subjects in the working age 
(mean age 54) with a higher involvement in paid work (75%).25 By doing so 
we were able to investigate the effectiveness of HMW-HA in a population 
in which knee OA levels are rising and in which surgical treatments like 
arthroplasty are less eligible due to high revision rate and limited life span 
of the prosthesis.21-23 We showed that in this population, intra-articular 
HMW-HA leads to clinically relevant improvement in pain, function and PGA. 
Since the costs from loss of productivity at work due to knee OA are high in 
patients in the working age, the treatment with HMW-HA could also result in 
certain economic benefits.24 This was investigated in the parallel economic 
evaluation of the VISK study, in which we report that intra-articular HMW-HA 
in knee OA is probably cost-effective in this population.25
To date, 2 other studies compared HMW-HA added to usual care to usual care 
only.34, 35 The same HMW-HA derivative as in our study was investigated. Both 
studies imposed no limitation on maximum age at time of inclusion, which 
probably contributed to the relatively low proportion of subjects involved in 
a paid occupation (19 to 34%).34, 35 In the first study statistically significant 
more patients in the intervention group were responder to therapy at final 
follow-up of 9 months.35 The percentage of responders was higher in both 
study groups compared to our study. Also no restriction on the radiologic 
degree of OA was imposed in this study and the minimal pain score at entry 
was higher (4 against 2).35 The inclusion of clinically more severe OA patients 
may have resulted in a larger percentage of responders in both groups 
since these patients are more likely to benefit from their treatment for knee 
OA. The second study reported statistically significant differences on pain, 
function and stiffness (WOMAC questionnaire), and on PGA in favour of the 
intervention group.34 A decrease of 38% in the pain scale in the intervention 
group was reported, compared to a 13% decrease in the control group. 
K&L grade IV was excluded but multiple series of intra-articular injections 
with HMW-HA were allowed, in contrast to 1 series of HMW-HA in our study. 
The effectiveness results of our study are in line with the results of both 
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aforementioned studies. Including our study, the results of the 3 studies 
showed that the primary effectiveness outcome parameters improve at least 
20% when HMW-HA is added to the usual care treatment.
Intra-articular injections with HMW-HA are frequently accompanied by 
transient pain or swelling of the knee. The procedure itself also includes 
a risk of inducing septic arthritis.16, 17 At 6 weeks, a statistically significant 
difference of subjects receiving HMW-HA in our study reported flares or 
flare-like symptoms of the study knee compared to the control group (35% 
vs 10%, p=>0.001) in the control group. No septic arthritis occurred. These 
results on local adverse events (AE) are similar compared to other studies.34, 
35 In our opinion the reduction of knee pain and the improvement of function 
outweigh the increase of transient flare like symptoms.
The follow up of the VISK study was 52 weeks. Optimal pain decrease after 
administration of intra-articular HMW-HA is seen at about 3 months though.16, 
18 A shorter follow-up period, closer to the peak effectiveness, encloses the 
risk of underestimation of possible health effects. Effects on pain function 
and PGA can occur during a longer period than the peak effectiveness. A 
longer follow-up also allows for assessment of the course of these effects. To 
ensure that these matters were accounted for, the current follow-up period 
of 52 weeks was chosen.
This study has limitations that need to be addressed. The study design of the 
VISK study did not include a placebo group. Previous research showed that 
placebo effects in intra-articular HA studies are above average.36 It is thus 
likely that part of the beneficial effect in the intervention group is explained 
by the placebo effect. There were 2 main reasons to opt for this specific 
study design without a placebo group. First, evidence from high quality 
studies in meta-analyses showed that HMW-HA is efficacious for knee OA.18-20 
The next logical step was to investigate the actual effectiveness of HMW-
HA, thereby accepting the fact that part of the possible beneficial effects is 
probably explained by the placebo effect. Second, a study design in which 
the intervention (HMW-HA) is compared to the usual care treatment (and not 
to placebo) in an everyday clinical setting is required to be able to facilitate a 
parallel economic evaluation which was also part of the VISK study project.25-27 
The target population of our study can be described as secondary care 
patients with symptomatic and mild to moderate knee OA. We therefore 
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included subjects with K&L grade I-III and a minimal VAS pain score of 2. 
Patients who were more likely to benefit from surgical therapy like TKA or 
osteotomy, or from rheumatologic treatment where excluded in this study 
(e.g. K&L grade IV, substantial varus/valgus deformation, inflammatory 
arthritis). We aimed to avoid measuring effects strongly related to other 
factors than the intervention itself (e.g. recent or planned knee surgery, 
daily steroid use) and to avoid possible harm due to the intervention (e.g. 
allergies, pregnancy). Applying these criteria may have consequences for the 
generalizability of the results. It is for example uncertain if the effectiveness 
results also extend to other patient groups who might benefit from HMW-
HA treatment, like knee OA patients not fit for surgery who are in need of 
surgical therapy.
Conclusion
We conclude that intra-articular injections with HMW-HA added to usual care 
is effective in patients in the working age. It results in more responders to 
therapy and improvement in pain, function and PGA.
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Additional file 1
Patients experiencing knee treatment related adverse events (n=156)
    6  (n) 13  (n) 26  (n) 39  (n) 52  (n)
  intervention group (n=77)
Flare knee 36% (27) 8% (6) 8% (6) 8% (6) 6% (5)
Gastro-intestinal complaints 7% (5) 3% (2) 5% (4) 5% (6) 4% (4)
Other 11% (8) 8% (8) 5% (5) 4% (3) 4% (3)
Total 45% (40) 15% (16) 16% (15) 13% (15) 12% (12)
control group (n=79)
Flare knee 10% (7) 16% (11) 8% (6) 7% (5) 11% (8)
Gastro-intestinal complaints 6% (7) 12% (11) 3% (3) 4% (3) 3% (3)
Other 10% (9) 9% (6) 7% (5) 1% (1) 16% (12)
Total 18% (23) 27% (28) 15% (14) 11% (9) 20% (23)
Patients experiencing  other adverse events (n=156)
Intervention group (n=77) n Control group (n=79) n
Removal of staple from tibia 1 Gout 1
Radius fracture 1 Spondylolisthesis 1
Fibroadenoma 1 Removal of seborrheic verruca 1
Abducens nerve paresis 1 Partial parotidectomy due to Whartin tumor 1
Peroneal tendon ganglion 1 Dermatological flebectomy 1
Ribfracture 1 Actinic keratosis  1
Neurofibromatosis 1
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Abstract
Objectives
Knee osteoarthritis (OA) is associated with high medical costs and especially 
with high productivity costs, in particular in patients in their working years. 
High molecular weight (HMW) hyaluronic acid (HA) is an alternative treatment 
for non-steroidal anti-inflammatory drugs, which are known for their serious 
side-effects. The cost-utility of intraarticular HMW-HA treatment in these 
patients is unknown, however, and was assessed in this study.
Methods
Secondary care patients ages 18 and 65 years with knee OA were randomized 
to usual care + HMW-HA (intervention group) or usual care only (control 
group). A cost-utility analysis over 52 weeks from the societal and health care 
perspective was performed. Uncertainty for costs, effects and cost-utility 
ratio was analysed by non-parametric bootstrapping. Baseline imbalance 
adjustment was done by inversed probability of treatment weighting.
Results
In total, 156 subjects were included (intervention group n=77, control group 
n=79). The total of productivity and medical costs was €475 higher in the 
intervention group (€7.754, 95% Confidence Interval (95% CI) 5.426, 10.436 
versus €7.270 (€95%CI 5.453, 9.262). The amount of quality-adjusted life years 
(QALYs) gained during followup was also higher in the intervention group 
(0.779 versus 0.727). This resulted in an incremental cost-effectiveness ratio 
of €9.100/QALY from a societal perspective and €8.700/QALY from a health 
care perspective. When the maximum willingness to pay for conditions 
similar to knee OA is considered, the probability on cost-effectiveness is 64% 
and 86% respectively. 
Conclusion
Intraarticular HMW-HA added to usual care for knee OA is probably cost-
effective in the treatment of knee OA.
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Introduction
Knee osteoarthritis (OA) is the most common type of OA. It results in 
high disability, high healthcare use and high associated costs.1-3 The initial 
treatment for patients with knee OA consists of pain medication including 
acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), physical 
therapy and lifestyle recommendations.4 Oral NSAIDs may cause serious 
gastrointestinal and cardiovascular side effects, warranting limited use only.5-
7 An alternative treatment option is the use of intra articular injections with 
hyaluronic acid (HA).8 Secondary care physicians like orthopaedic surgeons 
and rheumatologists can opt for such treatment, especially when contra 
indications to NSAIDs exist, or when a knee prosthesis is not indicated for 
example in younger patients. Within the spectrum of HA products, the use of 
HA derivatives with a high molecular weight (HMW) results in more favourable 
effects on clinical parameters like pain and function.8-10
To inform decision making on reimbursements and implementation of 
treatments, economic evaluations of treatments are useful and sometimes 
even mandatory. They provide insight in the effects and associated costs 
of the treatment and supply policy and decision makers in health care 
with useful information to support their decisions.11, 12 Until this point two 
economic evaluations investigated the value of HMW-HA for knee OA in 
a real world clinical setting.13, 14 Favourable cost-effectiveness results of 
HMW-HA were reported, but both studies included subjects of higher age 
and subjects were often not involved in a paid occupation.13, 14 A study in 
subjects in their working years who are more likely to be employed and 
relatively younger than the general OA population, will extend the knowledge 
on the cost-effectiveness of HMW-HA. Since productivity costs account 
for the vast majority of the total costs in this population, the availability 
of a safe and effective local therapy could also offer important economic 
benefits alongside health care benefits.15 We therefore determined the cost-
effectiveness of intra articular HMW-HA added to usual care compared to 
usual care only in secondary care patients with symptomatic knee OA in their 
working years.
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Patients and methods
This cost-utility analysis was performed alongside a randomized controlled 
trial (RCT) in which intraarticular HMW-HA added to usual care was compared 
to usual care only in the treatment of symptomatic knee OA subjects. The 
primary effectiveness outcome parameters included knee pain, function 
and patient-rated improvement. The effectiveness results were positive 
and predominantly statistically significant favouring the HMW-HA treated 
group, and will be presented in a forthcoming publication. The current paper 
focusses on the cost-utility analysis only.
Both analyses are part of the VIScosupplementation for Knee osteoarthritis 
(VISK) study, approved by the local Medical Ethics Committee and performed 
in compliance with the Declaration of Helsinki and Good Clinical Practice 
guidelines. The followup was 52 weeks and data on productivity costs, medical 
costs and quality of life was collected through questionnaires at baseline, 6, 
13, 26, 39 and 52 weeks. 
Study sample
Inclusion of eligible subjects took place between May 2009 and May 2010 in 
2 hospitals (1 academic, 1 non-academic) in The Netherlands. Consecutive 
knee OA patients at the outpatient orthopaedic department meeting the 
inclusion criteria were eligible. Patient’s age was set between 18 and 65 since 
this was the pensionable age in The Netherlands at time of study. Inclusion 
criteria were: pain >3 months, pain severity >2 on numeric rating scale (NRS), 
Kellgren/Lawrence (K/L) grade I to III. Exclusion criteria were intraarticular 
HA injections  <1 year, steroid injection <3 months, arthroscopy <6 months, 
synovectomy, tibial osteotomy <12 months, scheduled knee surgery <12 
months, varus/valgus deformity >12°, chondrocalcinosis, dermatologic knee 
disorders, allergy on HMW-HA components, (planned) pregnancy or lactation, 
inflammatory arthritis, severe hip OA, non-knee related regular analgesic 
use, daily steroid therapy, poor general health, conditions interfering with 
functional assessments (bed ridden, wheelchair, unable to walk 50 steps 
unaided), alcoholism, patients unable to attend followup and insufficient 
command of the Dutch language.
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Sample size, randomization and masking
The sample size was calculated to detect a between group difference of 
20% on the primary clinical effectiveness parameter (responder to therapy 
as defined by Outcome Measures in Rheumatology–Osteoarthritis Research 
Society International criteria) at 52 weeks.13, 16 A power of 80% and an alpha 
of 0.05 resulted in a required sample size of 128 subjects in total. Anticipating 
20% potential dropout rate over 1 year, the final required sample size was 
set at 154 subjects. Randomization took place after informed consent was 
signed. Concealed randomization was performed by computer generated 
lists with randomly assigned blocs of 2, 4, 6, 8 or 10 subjects. An independent 
employee performed the randomization. Stratification took place for the 
radiologic degree of OA and per orthopedic surgeon responsible for injections 
(2 per hospital, 4 in total). The investigator responsible for assessment and 
analyses of the data was blinded for the treatment allocation. Due to the 
study design, subjects and orthopedic surgeons could not be blinded.
Interventions
Subjects received 3 weekly intraarticular injections with Hylan G-F 20 (Sanofi) 
added to usual care (intervention) or they received usual care only (control).
Hylan G-F 20 is the HMW-HA derivative with the highest molecular weight 
available for clinical use (6000 kilodaltons). The injections were performed by 
2 experienced knee pathology orthopedic surgeons per hospital through the 
superolateral approach.17
Usual care was defined accordingly to guidelines of the Dutch Orthopedic 
Association, which includes pain medication including acetaminophen or 
NSAIDs when necessary; physical therapy and lifestyle recommendations.4 
No treatment restraints to the treating orthopedic surgeons were imposed 
in order to maintain the pragmatic character of the trial.
Productivity and medical costs
Productivity costs involved costs due to lost productivity while being present 
at work, costs due to absence from work and costs for unpaid work like 
household work by others.18-23 
The Productivity and Disease Questionnaire (PRODISQ) was used for the 
measurement of knee-related productivity costs.24 It includes knee-related 
92 Chapter 5
absence from work and knee-related lost productivity while being present 
at work.22, 24 Subjects were asked to rate the quality and quantity of work 
performed on their last work day compared to a regular workday on a 
10-point numeric rating scale (where 0=no quantity/quality and 10=normal 
quantity/quality). Due to the high correlation between both scales only 
the quantity scale was used for the productivity loss analyses.25 To assess 
compensational mechanisms for productivity loss in unpaid activities (e.g., 
household) due to knee OA, subjects were asked to indicate the amount of 
work taken over by others. Productivity costs were valued according to the 
Dutch guideline tariffs.26
Medical costs included knee-related physician and paramedical therapist 
visits, use of aids (e.g., braces, inlay soles), home care use, knee-related 
surgery and medication use. Medication costs included prescription fees 
pharmacists receive per prescription.26 Resources were valuated according 
to Dutch guideline tariffs.26 If prices were unavailable (e.g., homeopath tariffs), 
the tariff was calculated based on mean tariffs charged by different practices. 
The consumption of diagnostic imaging was retrieved from the hospitals 
patient information systems and its tariffs were obtained from the Dutch 
Health Care Authority.27 Tariffs for knee OA-related surgery were obtained 
from the participating hospitals. Tariffs for mobility aids were obtained from 
qualified mobility aids homecare suppliers. Costs from sustainable aids 
(crutches, etc) were calculated with respect to the depreciation time (2 years).
QoL assessment
QoL was assessed by the 3-level EuroQol questionnaire (EQ-5D).28, 29 This 
questionnaire contains 5 dimensions (mobility, self-care, activity, pain and 
anxiety) and each domain can be scored at 3 levels (no problems, some 
problems, serious problems). The utility values derived from the EQ-5D 
can range from -0.329 (worst situation) to 1 (perfect health) in the Dutch 
situation.30 The between group difference in the area under the curve of the 
QoL scores over 52 weeks was calculated to assess the QoL gain per year in 
quality-adjusted life years (QALYs).
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Analyses
Patients were analyzed according to the intention-to-treat principle. The 
cost-utility analyses were conducted from a societal perspective (medical 
and productivity costs) and from a health care perspective (medical costs 
only) using the friction cost method. This method accounts for the ability 
of organizations to restore productivity within certain timespan in case 
of productivity loss.31 Missing values were imputed by means of linear 
intrapolation. In few cases, only the baseline data were available (n=4, control 
group). In these cases the baseline observations were carried forward.
Cost utility analyses are sensitive for utility imbalances present at baseline.32, 
33 To generate unbiased estimates of the difference in QALYs and costs 
across both treatment groups, inverse probability of treatment weighting 
(IPTW) was used to adjust for baseline differences in QoL and pain.34, 35 First, a 
logistic regression model was estimated to analyse the relationship between 
treatment assignment and baseline characteristics (QoL, pain scores, 
radiologic degree of OA). The regression results were then used to calculate 
how likely each patient was to receive the assigned treatment, based on their 
baseline characteristics. These probabilities were stabilized by multiplying 
them with 0.5, which is the average probability of being assigned to a 
certain treatment group.36 Covariate balance before and after weighting was 
assessed based on standardized bias. The standardized bias for continuous 
covariates is calculated by dividing the difference in means of the covariate 
between the intervention and control group by the SD.37 A standardized bias 
of <0.10 was considered acceptable. Ordinary least squares regression was 
applied on the weighted sample in order to estimate the difference in QALYs 
across both treatment groups and to calculate adjusted mean QALYs per 
treatment group. In this model, we adjusted again for the same baseline 
characteristics. Since adjustment for baseline unbalances was not necessary, 
this was done only to make the estimates more precise.38 The costs were 
analyzed in a generalized linear model with a log link. Given the sensitivity of 
cost models for the specification of the link function when non-categorical 
covariates are used, we did not include baseline characteristics in this mode 
(Stata softwarere, version 14).
The differences in mean adjusted QALYs and costs between treatment groups 
are expressed in the so-called incremental cost-effectiveness ratio (ICER), 
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which is interpreted as the additional costs per QALY gained. We present 
the ICER from the societal perspective and from the health care perspective 
(Microsoft Excel, version 97-2003).
The uncertainty for costs and health effects was assessed by means of non-
parametric bootstrapping, in which 5000 observations were randomly drawn 
from the available study.39 For each bootstrap sample, stabilized weights 
were calculated and the average (incremental) cost and health effects 
were estimated. The 95% confidence intervals (95% CIs) around the point 
estimates for costs and effects were determined by taking the 2.5th and 97.5th 
percentiles of these bootstrap replications. The incremental costs and effects 
for each bootstrap sample were displayed on a cost-effectiveness plane.40 
An acceptability curve was drawn to indicate the probability that the cost-
effectiveness ratio for HMW-HA is acceptable, given various thresholds for 
the maximum willingness to pay for 1 QALY gained (Microsoft Excel, version 
97-2003).41 
Results
Study population 
In total, 156 subjects were included, with 77 patients in the intervention 
group and 79 subjects in the control group (Table 1).  Mean age, percentage 
of female subjects and BMI were similar in both groups. Despite normal 
randomization, subjects in the intervention group showed slightly lower 
scores on QoL (0.68 versus 0.71) and higher scores on pain (pain during rest 
4.8 versus 4.1, pain during activity 6.5 versus 5.8). IPTW resulted in balanced 
pain and QoL scores in both groups (Table 1). The standardized bias for all 
adjusted scores was <0.10.
One subject in the intervention group received only 1 out of 3 injections with 
HMW-HA due to a painful first injection and 1 subject refused the intervention 
after allocation to this group. In the control group, 3 subjects were not 
motivated for further study participation after baseline measurements and 
randomization and 1 subject was lost to followup (see Supplementary Figure 
1). All subjects were retained in the analyses of their randomization groups.
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Table 1 Population characteristics (n=156)*
Intervention (n=77) Control  (n=79)
Age, yr 53.6 ± 8,6 54,8 ± 6,4
Women, no (%) 37 (48) 40 (51)
BMI, kg/m2 28.9 ± 5,2 29.2 ± 5,4
Quality of life† 0.68 ± 0,23 0,71 ± 0,24
After IPTW 0.69 ± 0,24 0.69 ± 0,24
Pain rest‡ 4.8 ± 2,5 4.1 ± 2,6
After IPTW 4.4 ± 2.6 4.5 ± 2.6
Pain activity‡, 6.5 ± 2,4 5.8 ± 2,4
After IPTW 6.4 ± 2.5 6.1 ± 2.5
Paid work, n (%) 58 (75) 59 (74)
Hours/week 30.7 ± 11,3 32.8 ± 12,1
Job type, no (% in paid work)
Agriculture 2 (3) 2 (3)
Industry 9 (12) 5 (6)
Commercial services§ 29 (38) 32 (41)
Noncommercial services¶ 13 (17) 17 (22)
Government 5 (7) 3 (4)
* Values are the mean ± SD unless indicated otherwise. IPTW = inverse probability of treatment weighting. 
† On the EuroQol questionnaire (where  -0.329 = worst, 1 = best). ‡ On a numeric rating scale (where 0 = no 
pain, 10 = worst pain). § E.g., bank, company, store.¶ E.g., health care, education.
Productivity and medical costs
Table 2 shows the unadjusted (before IPTW) mean annual knee-related 
productivity losses, medical resource use and their associated costs including 
the largest cost drivers over 52 weeks followup. Supplementary Tables 
1 and 2 show the unadjusted subdivisions per time point of these items. 
Supplementary Table 3 shows the prices and tariffs used.
At final followup, the unadjusted mean productivity costs as well as the 
unadjusted mean medical costs were both higher in the intervention group. 
Concerning the productivity costs, decreased productivity while being 
present at work was the largest cost driver in both groups, accounting for 
51% (intervention group) and 60% (control group). The costs associated with 
knee-related surgery were the main cost drivers within the medical costs. 
Although only 9 knee surgery procedures in the intervention group and 7 in 
the control group were performed, these surgical procedures did account 
for 36% and 32% of the medical costs in both groups, respectively. 
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After adjustment of baseline imbalances by means of IPTW, the total adjusted 
costs at final followup were higher in the intervention group (€7.745 (95%CI 
5.426, 10.436)) compared to the control group (€7.270 (95%CI 5.453, 9.262)). 
This resulted in an adjusted annual cost difference of €475 (95%CI -2.686, 
3.636) associated with the use of HMW-HA.
This cost difference was mainly due to higher adjusted medical costs in the 
intervention group (€1.586 (95%CI 1.125, 2.112)) compared to the control 
group (€1.130 (95%CI 713, 1.667)). The adjusted productivity costs were 
similar in both groups, with €6.160 (95%CI 4.134, 8.462) compared to €6.141 
(95%CI 4.457, 7.977) in the control group. 
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Table 2 Annual unadjusted costs and largest contributors (n=156)*
Intervention (n=77) Control (n=79)
No. Costs No. Costs
Productivity losses and costs, hours
Unpaid work 107 ± 219 €1.340 ± €2.742 132 ± 241 €1.655 ± €3.013
Work absence 62 ± 185 €1.847 ± €5.557 21 ± 73 €638 ± €2.152
Present at work 110 ± 191 €3.315 ± €5.739 117 ± 196 €3.500 ± €5.876
Total productivity costs† €6.502 ± €9.744 €5.792 ± €7.442
Medical consumption and costs‡
Physician, visits
General practioner 1 ± 2 €19 ± €62 0 ± 1 €8 ± €24
Orthopaedic surgeon 2 ± 3 €0 ± €3 1 ± 2 €120 ± €165
Total 3 ± 4 €218 ± €284 2 ± 3 €175 ± €241
Therapist, visits
Physical therapist 8 ± 13 €285 ± €465 7 ± 11 €248 ± €379
Total 9 ± 14 €303 ± €482 8 ± 12 €267 ± €395
Homecare, hrs
Total 5 ± 24 €57±€301 4 ± 23 €45 ± €288
medical aids, units§
Inlay soles 0 ± 0 €33 ±€56 0 ± 0 €32 ± €55
Braces 0 ± 0 €15 ±€30 0 ± 0 €21 ± €34
Total 1 ± 2 €71 ±€85 2 ± 2 €72 ± €75
Medication, (units
Acetaminophen 271 ± 577 €6 ±€13 214 ± 435 €5 ± €10
NSAID 121 ± 193 €45 ±€71 92 ±175 €34 ± €65
Gastroprotective 49 ± 118 €25 ±€60 47 ±123 €24 ± €62
Total 516± 732 €117 ±€194 464 ±621 €134 ± €220
Study medication
Total 1 ± 0 €240 ±€0 - - -
Imaging, units
X-ray 1 ± 1 €30 ±€50 0 ± 1 €14 ± €25
Total 1 ± 1 €45 ±€72 0 ± 1 €21 ± €46
Surgery, procedures
Total 0 ± 0 €595 ±€2.045 0 ± 0 €344 ± €1.591
Total medical costs €1.647 ± €2.349 €1.059 ± €2.012
Total annual costsa €8.148 ± €11.325 €6.851 ± €8.133
* Values are the mean ± SD. NSAID = nonsteroidal antiinflammatory drug. † Totals using friction costs method. 
‡ Largest contributors are displayed; categories do not add up to total. § Adjusted for depreciation time.
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Quality of life
From randomization to study end, the intervention group accrued more 
QALYs than the control group. The unadjusted data show an increase of the 
proportion of subjects who indicate no problems in the domains activities, 
mobility and anxiety/depression of the EQ-5D in both groups. This increase 
was highest in the intervention group. In the pain/discomfort domain an 
increase was seen in both groups and this increase reduced towards the 
end of the followup period in the intervention group. In the self-care domain 
the proportion of subjects indicating no problems remained about the same 
in both group throughout followup.
The average adjusted values were 0.779 QALY (95%CI 0.721, 0.793) in the 
intervention group and 0.727 (95%CI 0.668, 0.742) in the control group. This 
resulted in a difference of 0.052 (95%CI 0.014, 0.092). 
Table 3 Total adjusted costs, adjusted effects, differences and cost-utility analysis at final followup*
Intervention (n=77) Control (n=79) Difference
Costs (95%CI) †
Productivity costs 6.160 (4.134, 8.462) 6.141 (4.457, 7.977) 19 (-2.752, 2.841)
Medical costs 1.586 (1.125, 2.112) 1.130 (713, 1.667) 456 (-252, 1.147)
Total costs 7.745 (5.426, 10.436) 7.270 (5.453, 9.262) 475 (-2.686, 3.636)
QALYs (95% CI) 0,779 (0,721, 0,793) 0,727 (0,668, 0,742) 0,052 (0,014, 0,092)
Perspective
Societal €9.061‡
Healthcare €8.701‡
* QALY = quality-adjusted life year. † Values are in € (95% confidence interval). ‡ Incremental cost-utility 
ratio (€/QALY).
Cost-utility analysis 
From the societal perspective, the gain of 0.052 QALY’s in the intervention 
group along with its associated cost increase of €475 led to in an ICER of 
€9.061/QALY gained as a result of use of HMW-HA (Table 3). From the health 
care perspective (medical costs only), the ICER was €8.701 per QALY gained 
As shown in the cost-effectiveness planes from the societal and medical 
perspective (Figures 1 and 2), over 99% of the bootstrap replications resulted 
in positive estimates of incremental health effects due to the use of HMW-
HA. From the societal perspective, the probability that the intervention 
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is associated with additional costs is 60% as is represented in the upper 
half of the cost-effectiveness plane. The probability that the intervention is 
dominant, with HMW-HA resulting in better health effects and cost-savings, 
is 39% (Figure 1, south-east quadrant). From a health care perspective, the 
probability that the intervention leads to a cost increase is 90%, and the 
probability of dominance of the intervention from this perspective is 9% 
(Figure 2). 
Figure 1 Cost-effectiveness plane from the societal perspective
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Figure 2 Cost-effectiveness plane from the health care perspective
According to the latest report of the Dutch Health Care Institute, the 
maximum willingness to pay for conditions with a disease burden similar to 
knee OA would be up to €20.000/QALY.42 Considering this upper threshold of 
€20.000/QALY, the probability that HMW-HA is cost-effective is 64% from the 
societal perspective and 86% from the medical perspective (Figure 3). 
Figure 3 Acceptability curves from the societal and health care perspective. ICER = incremental 
cost-effectiveness ratio.
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Discussion
This health-economic evaluation is the first to our knowledge to study the cost-
effectiveness of intraarticular HMW-HA added to usual care in knee OA patients 
in their working years. We found that adding HMW-HA to usual care for knee 
OA resulted in a gain in QoL of 0.052 (95%CI 0.014, 0.092) over 52 weeks. 
The gain in QoL was accompanied with a cost increase, resulting in a cost-
utility ratio of approximately €9.100/QALY gained from the societal perspective 
and approximately €8.700/QALY gained from the health care perspective. The 
uncertainty analyses indicate a probability of 99% that HMW-HA in knee OA 
will result in positive health effects. Considering the maximum willingness to 
pay of €20.000/QALY for conditions similar to knee OA, the probability on cost-
effectiveness of HMW-HA is 64% from the societal perspective and 86% from 
the medical perspective.42
To date, only 2 (commercially funded) studies compared HMW-HA added to 
usual care to usual care.13, 14  In a Canadian study, a greater increase in QoL and 
in costs was found after 12 months followup in the intervention group.14 The 
ICER equalled about €7.100/QALY (exchange rate at current study inclusion) 
from the societal perspective, which is less than the ICER we found. The included 
population was of higher age (63 years) and more subjects were not involved 
in a paid occupation was also higher (68%). Productivity loss when present at 
work was not accounted for in that study. Together, these factors may have 
contributed to the reported lower ICER than we found in our population in 
their working years.
A French study reported an ICER of -€1,78 favouring the intervention group 
after 9 months of followup.13 The cost-effectiveness ratio was based on a 
clinical effectiveness parameter (Lequesne index). At final followup, total costs 
were similar in both groups, but HMW-HA was found to be 18% more effective. 
Uncertainty analyses showed a probability of 91% that the intervention was 
dominant (positive health effects, lower costs). No age restriction was imposed 
and productivity loss while being present at work, productivity loss in unpaid 
work and compensation for household work by others were not accounted 
for, which may have contributed in the differences in outcome compared to 
our study.
Furthermore, a cost-effectiveness analysis was performed instead of a cost-
utility analysis. The Lequesne index measures knee-related pain/discomfort, 
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impairments in walking distance and activities in daily life, whereas the EQ-5D 
(as used in the current cost-utility analysis) also comprehends the domains 
self-care and anxiety. Thus all health effects due to HMW-HA may not have 
been accounted for.
In contrast to the aforementioned studies, the study subjects in the current 
investigation were more often involved in a paid occupation. This fact is 
represented in the relatively large portion of productivity costs in both groups 
(approximately 80% of the total costs) and these findings are in line with 
previous research.15, 19, 43 It remains uncertain how possible differences in health 
care systems and reimbursement politics in different countries may have 
influenced the comparability of study results between both aforementioned 
studies and our study.
Several factors contributed to the favorable cost-utility ratio we found. Where 
the unadjusted data show that decreased productivity while being present at 
work was the largest cost driver in both groups, the higher costs related to 
being absent from work in the intervention group were mainly responsible for 
the between-group difference in productivity costs. The unadjusted medical 
costs in both groups were mainly driven by cost associated with knee-related 
surgery. These costs were higher in the intervention group. Together with the 
costs of the HMW-HA product itself, these were the costs mainly responsible 
for the higher medical costs in the intervention group. The unadjusted data also 
show that QoL was gained in both groups during followup and that more QoL 
was gained by the intervention group. Especially the domains activities, mobility 
and anxiety/depression of the EQ-5D were responsible for this difference in 
QoL gain. Altogether, despite the increase in costs in the intervention group, 
the relatively higher gain in QoL led to the current favorable cost-utility ratio.
As is customary in clinical cost-effectiveness analyses, the sample size of our 
VISK study was based on power calculations on clinical outcome parameter of 
the clinical effectiveness part of the trial.14, 44, 45 This calculation is not optimal, 
since costs generally show larger variances and a more skewed distribution 
than clinical outcome parameters.14, 44-48 Under ideal circumstances, sample 
size calculation would also be based on expected costs and QoL differences. In 
practice, sample sizes in the order of thousands instead of hundreds are then 
required. Such numbers are difficult to include in clinical practice and such a 
study is unlikely to be funded for. Nevertheless, the results of this cost-utility 
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analysis would have been more robust when derived from a larger sample. 
Therefore, the current results need to be interpreted with some reservations 
and in light of the sample size discussion.
After randomization, some variables, including utility, were imbalanced. Since 
baseline utility values are strongly correlated with QALY’s at final followup, 
this issue was addressed.32, 33 In order to generate unbiased estimates of the 
difference in QALY’s and costs we adjusted for baseline differences in QoL and 
pain by means of IPTW.34, 35 Failure to do so would have generated incorrect 
results that, at the end, could be misleading in decision making by health care 
professionals and reimbursement policy makers.33
The target population of our study can be described as patients with 
symptomatic and mild to moderate knee OA. For this reason, patients with K/L 
grade I-III and a minimal pain score of 2 were included.  Patients who were more 
likely to benefit from different kinds of therapy were excluded in this study (e.g., 
K/L grade IV, substantial varus/valgus deformation, inflammatory arthritis). We 
also aimed to avoid measuring effects strongly related to other factors than 
the intervention itself (e.g., recent or planned knee surgery, daily steroid use). 
We avoided possible harm due to the intervention (e.g., allergies, pregnancy). 
The use of these criteria may have consequences for the generalizability of the 
results. It is for example uncertain if the current cost-utility results also extend 
to other patient groups who might benefit from HMW-HA treatment, like older 
patient with more severe knee OA or patients not fit for surgery who are in 
need of surgical therapy.
This study is the first economic analysis on the value of intraarticular HMW-HA 
in subjects in their working years. All relevant cost items were assessed. We 
found that adding HMW-HA to usual care is likely to result in an increase in QoL, 
which is accompanied by a cost increase. The probability on cost-effectiveness 
of HMW-HA is 64% from the societal perspective and 86% from the medical 
perspective, considering the maximum willingness to pay of €20.000/QALY for 
similar conditions to knee OA.42
We conclude that the treatment with intraarticular HMW-HA in knee OA 
patients in their working years is probably cost-effective for the Dutch health 
care situation. The current results support patients and physicians in the 
decision concerning treatment with HMW-HA in knee OA. It provides useful 
information in the matter of reimbursement of HMW-HA.
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Supplementary Figure 1 Flowchart
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Supplementary table 1 Mean unadjusted productivity loss and medical consumption per 
time point per subject (n=156)
Intervention (n=77)
6 sd 13 sd 26 sd 39 sd 52 sd
Productivity loss hrs
Unpaid work 12 33 11 39 33 76 27 67 24 52
Absence from work 14 55 7 30 14 64 13 60 13 67
Present at work 12 26 13 32 28 76 35 94 23 59
Total productivity loss 38 63 31 70 75 116 75 134 60 99
Medical consumptiona
Physician visits
General practioner 0 0 0 0 0 1 0 1 0 1
Orthopaedic surgeon 0 1 0 1 0 1 0 1 1 1
Total 0 1 0 1 1 1 1 2 1 2
Therapist visits
Physical therapist 1 3 1 3 2 4 2 5 2 4
Total 2 3 1 3 2 4 2 5 2 4
Homecare hours
Total 2 14 0 2 2 8 1 4 1 4
Medical aids unitsb
Inlay soles 0 0 0 0 0 0 0 0 0 0
Braces 0 0 0 0 0 0 0 0 0 0
Total 1 1 1 1 1 1 1 1 1 1
Medication units
Acetominophen 30 69 39 91 72 174 64 169 67 180
NSAID 17 34 18 38 42 102 25 57 18 48
Gastroprotective agents 7 15 6 16 10 32 14 36 12 34
Total 60 94 69 117 147 234 124 198 116 222
Study medicationc
Total 1 0 - - - - - - - -
Imaging units
X-ray 0 0 0 0 0 0 0 1 0 1
Total 0 0 0 0 0 0 0 1 0 1
Surgery procedures
Total 0 0 0 0 0 0 0 0 0 0
Control (n=79)
6 sd 13 sd 26 sd 39 sd 52 sd
Productivity loss hrs
Unpaid work 11 23 11 26 36 75 39 79 36 79
Absence from work 7 39 7 41 1 9 3 20 3 20
Present at work 16 42 15 32 27 67 28 65 31 92
Total productivity loss 34 55 33 57 64 98 71 106 70 117
109
5
Cost-utility analysis of high molecular weight hyaluronic acid 
Medical consumptiona
Physician visits
General practioner 0 0 0 0 0 0 0 0 0 0
Orthopaedic surgeon 0 1 0 0 0 1 0 1 0 0
Total 0 1 0 1 0 1 0 1 0 1
Therapist visits
Physical therapist 2 3 1 3 1 4 1 4 1 2
Total 2 3 2 3 2 4 2 4 1 4
Homecare hours
Total 0 2 0 3 0 4 1 6 1 10
Medical aids unitsb
Inlay soles 0 0 0 0 0 0 0 0 0 0
Braces 0 0 0 0 0 0 0 0 0 0
Total 1 1 1 1 1 1 1 1 1 1
Medication units
Acetominophen 32 71 25 71 52 139 59 144 47 145
NSAID 12 32 18 43 10 37 22 64 30 79
Gastroprotective agents 5 15 8 21 10 36 10 35 14 35
Total 74 120 66 96 103 193 107 190 113 205
Study medicationc
Total 0 0 - - - - - - - -
Imaging units
X-ray 0 0 0 0 0 0 0 0 0 0
Total 0 0 0 0 0 0 0 0 0 0
Surgery procedures
Total 0 0 0 0 0 0 0 0 0 0
aLargest contributors are displayed, categories do not add up to total, bAdjusted for depreciation time, 
cSeries of 3 intra articular injections of HMW-HA
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Supplementary table 2 Mean unadjusted productivity costs and medical costs per timepoint 
(€, n=156)
Intervention (n=77)
6 sd 13 sd 26 sd 39 sd 52 sd
Productivity costs
Unpaid 151 416 140 492 418 954 334 835 298 656 
Absent 413 1.666 214 921 415 1.945 402 1.805 402 2.028 
Present 364 788 384 969 836 2.283 1.045 2.833 685 1.759 
Total productivity 
costsa
928 1.719 738 1.618 1.669 2.904 1.781 3.444 1.385 2.521 
Medical costsb
Physican visits
General practioner 1 8 2 7 3 16 8 25 5 17 
Orth. surgeon 0 0 0 3 0 0 0 0 0 0 
Total 33 63 35 72 44 77 45 103 61 135 
Therapist visits
Physical therapist 54 118 41 98 58 149 67 164 66 155 
Total 54 118 45 100 59 149 77 177 68 155 
Homecare 22 173 3 30 19 105 6 56 6 56 
Total 22 173 3 30 19 105 6 56 6 56 
Medical aidsc
Inlay soles 8 38 8 37 5 19 7 38 5 18 
Braces 3 21 3 21 3 21 3 25 2 19 
Total 16 31 15 28 15 44 15 28 10 18 
Medication
Acetominophen 1 2 1 2 2 4 1 4 2 4 
NSAID 6 13 7 14 16 38 9 21 7 18 
Gastroprotective 3 8 3 8 5 16 7 18 6 17 
Total 14 23 16 30 32 72 30 55 24 47 
Study medicationd 240 0 
Imaging
X-ray 6 17 1 7 7 16 10 30 6 22 
Total 6 17 1 7 14 39 14 43 9 30 
Operations
Total 0 0 12 107 12 107 235 1.209 336 1.646 
Total medical costs 385 424 128 266 195 594 423 1.671 515 2.087 
Total costs 1.314 1.746 866 1.606 1.865 2.932 2.204 3.729 1.900 3.249 
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Control (n=79)
6 sd 13 sd 26 sd 39 sd 52 sd
Productivity costs
Unpaid 135 285 137 326 446 933 489 987 448 987 
Absent 204 1.153 213 1.207 43 278 100 593 78 600 
Present 488 1.259 436 969 796 2.014 848 1.947 932 2.775 
Total productivity 
costsa
827 1.502 785 1.502 1.285 2.072 1.436 2.228 1.459 2.766 
Medical costsb
Physican visits
General practioner 2 10 2 7 0 3 1 4 2 12 
Orth. surgeon 22 61 18 37 37 74 24 58 20 47 
Total 40 101 27 51 43 86 33 73 31 74 
Therapist visits
Physical therapist 66 111 51 105 54 137 51 126 26 79 
Total 69 113 52 105 60 150 55 126 31 83 
Homecare
Total 3 25 6 35 6 55 12 77 19 122 
Medical aidsc
Inlay soles 6 15 7 28 5 16 7 15 6 16 
Braces 3 12 3 13 5 23 5 19 6 26 
Total 12 16 15 25 15 22 15 20 16 22 
Medication
Acetominophen 1 2 1 2 1 3 1 3 1 3 
NSAID 5 12 7 16 4 14 8 24 11 29 
Gastroprotective 2 8 4 11 5 18 5 18 7 18 
Total 22 58 23 36 33 80 22 45 34 58 
Study medicationd
Imaging
X-ray 5 14 1 7 3 13 3 11 3 14 
Total 5 14 1 7 10 38 3 11 3 14 
Operations
Total 0 0 89 802 12 107 111 894 132 995 
Total medical costs 151 328 213 1.061 179 538 251 1.246 265 1.368 
Total costs 978 1.533 998 2.090 1.464 2.110 1.687 2.476 1.724 3.252 
`a Totals using friction costs method, b Largest contributors are displayed, categories do not add up to total, 
c Adjusted for depreciation time, d Series of 3 intra articular injections of HMW-HA
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Supplemental Table 3 Unit prices productivity and medical costs (€)  
Productivity costs (hour)
Paid work 30,02 
Unpaid work 12,50 
Medical costs
Physician / therapist (consult) Medication (unit)
General physician 28,00 Pharmacists prescription fee 5,99 
Sports physician 30,00 Pain medication
Physical therapist 36,00 Acetominophen 0,02 
Practice therapist 35,00 Brufen 400 0,17 
Medical specialist Diclofenac 75 0,11 
Non-academic hospital 64,00 Arthrotec 75/0,2 0,37 
Medical specialist Celebrex 200 0,79 
Academic hospital 129,00 Tramadol 50 0,13 
Company physician 62,50 Oramorph 0,29 
Emergency room visit 151,00 Prednisolon 1,20 
Homeopath 36,00 Antacids
Podiatrist 36,00 Esomeprazol 20 0,64 
Physical therapist fitness 8,00 Esomeprazol 40 0,91 
Dietician 27,00 Pantoprozol 20 0,51 
Sports masseuse 26,00 Pantoprozol 40 0,20 
Aids (unit) Pantopac 1,76 
Cold compress 1,95 Omeprazol 20 0,31 
Hot compress 1,95 Omeprazol 40 0,89 
Crutches 39,75 Ranitidine 150 0,06 
Walking stick 19,95 Gels
Orthopaedic inlay 126,00 Voltaren 0,84 
Bandage 22,50 Artrosilium                                       0,89 
Brace 75,00 Tantum                                            1,42 
Tape 1,50 IJslander                                         0,50 
Orthopaedic shoes 125,00 Perozin                                           0,85 
Shower chair 450,00 Spiroflor 0,60 
Adjusted bicycle 3.200,00 
Wheelchair 358,00 
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Surgery (procedure) Tigerbalm 1,96 
Non-academic hospital Symphosan                                         0,65 
Total knee prosthesis 6.072,07 Vacol ointment                                        0,50 
Inilateral knee prosthesis 6.072,07 Biofreeze                                         0,59 
High tibial osteotomy 1.430,84 Traumeel                                          1,08 
Arthroscopy 622,45 Perskindol 0,50 
Bending knee under anaesthesia 524,14 Reflex                                            1,20 
Hospital day 320,42 Miscellaneous
Academic hospital Acetominophen+coffein 0,10 
Total knee prosthesis 5.787,87 Acetominophen+codein 0,24 
High tibial osteotomy 2.325,90 Zaldiar 0,41 
Hospital day 575,00 Morfine 0,52 
Imaging (unit) Amytriptilline 0,99 
X-ray 43,38 Glucosamine 0,28 
Ultrasound 49,09 Chondroitine 0,65 
CAT scan 152,96 
MRI scan 187,21 
Scintigraphy 126,71 
SPECT scan 126,71 
Abbreviations:  CAT: Computerize Axial Tomography, MRI: Magnetic Resonance Imaging, SPECT: Single 
Photon Computed Tomography.
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Intra-articular hyaluronic acid (HA) therapy as a treatment modality for 
symptomatic knee osteoarthritis (OA) has been investigated for decades. 
With this thesis, focusing on different aspects of HA therapy in relative young 
patients with symptomatic knee OA who are in their working years, we aimed 
to add to the discussion on its effectiveness and its economic consequences 
in clinical practice.  
First, we conducted a systematic review to study the most accurate approach 
to administer HA into the knee joint. We examined the nature and extent of the 
productivity costs and the medical costs related to knee OA in non-surgically 
treated patients with a paid employment. The VISK study was conducted, 
which is a randomized controlled trial (RCT) to assess the effectiveness and 
cost-effectiveness of intra-articular HA therapy with a high molecular weight 
(HMW) derivative in symptomatic knee OA patients at the working age. 
Finally, we conducted a systematic review and meta-analysis to investigate 
the amount and nature of adverse events (AEs) related to the intra-articular 
administration of HA in the knee joint, and their possible relation with specific 
product characteristics of the HA derivative.
In this chapter the main results of this thesis are placed in a larger 
perspective. The limitations of the presented research are addressed and 
recommendations for future research are made.
Efficacy
The efficacy of intra-articular HA in the treatment of knee OA has been studied 
extensively. Dozens RCTs comparing HA to placebo have been performed 
since the first clinical experiments on HA as a treatment option for knee OA 
were conducted.1  
Despite the numerous clinical studies, controversy concerning the efficacy 
of HA for the treatment of knee OA existed. The debate on the efficacy 
inevitably led to the publication of systematic reviews. To date, 17 systematic 
reviews and meta-analyses have been published on the topic, generally 
reporting positive efficacy results of intra-articular HA on pain and/or function 
compared to placebo.2  These findings are not free of criticism. A meta-
analysis investigating trial inconsistencies in HA studies for knee OA reported 
that intra-articular HA resulted in  HADSFa better effect on pain reduction 
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compared to placebo, but the presence of publication bias and the risk of 
selective outcome reporting suggests that the clinical effect is only small.3 
In another systematic review poor methodological quality and reporting 
quality of the included trials were indicated as a major limitation. The authors 
conclude that trial size, blinded outcome assessment and publication status 
were associated with the effect size of intra-articular HA therapy for knee 
OA.4
Eventually, 2 systematic reviews were conducted, both investigating the 
already published meta-analyses on the efficacy of HA. These reviews report 
that the methodological quality between the included meta-analyses varies. 
The conclusions of the reviews both indicate HA as an effective intervention 
in the treatment of knee OA with moderate symptomatic benefit.1, 2 
Most placebo controlled RCTs investigated the efficacy of a single series 
of intra-articular HA. More recently, the focus has shifted to the evaluation 
of efficacy and safety of repeated courses of intra-articular HA. A recent 
systematic review and meta-analysis on this topic showed that throughout 
repeated courses pain reduction was either sustained or further reduced. 
No further safety risks were found.5
Effectiveness 
Based on the positive efficacy results from the Cochrane systematic review 
from 2006 the VISK study was designed.6 One of the goals was to investigate 
the actual effectiveness intra-articular HA in the treatment of knee OA in a 
patient group in the working age. In chapter 4 we report on the effectiveness 
results of the VISK study. We showed that intra-articular HA added to the 
usual (non-surgical) care for knee OA results in more responders to therapy 
according to the OMERACT-OARSI criteria after 12 months follow-up.7 We 
conclude that intra-articular injections with HMW-HA added to usual care 
is effective. It results in more responders to therapy and in improvement 
in pain, function and patient global assessment. Based on these results we 
recommend intra-articular HMW-HA as a therapeutic option in the non-
surgical management of symptomatic knee OA. 
To date, 2 other RCTs have compared HMW-HA added to usual care to usual 
care only. Our effectiveness results are in line with these studies in which 
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beneficial clinical results on pain and function are reported when intra-
articular HA is added to the usual care treatment for knee OA.8, 9
No long term follow-up RCTs on the effectiveness of intra-articular HA 
therapy for symptomatic knee OA have been published. The results of 2 
studies investigating 2 different large healthcare claims databases in the 
United States (US) show that the time from the initial diagnosis of knee 
OA by an orthopedic surgeon to the date of total knee replacement (TKR) 
surgery is significantly longer in knee OA patients treated with intra-articular 
HA, compared to patients who were not treated with HA. Depending on the 
investigated database, the difference in delay varied from 0.7 years to 2.9 
years.14, 15 The increase in time to TKR is reported to be dose dependent and 
associated with the number of treatment series administered.10 These results 
do need to be interpreted with reserve due the possibility of confounding by 
indication. 
Efficiency
Efficiency measures the effect of an intervention in relation to the costs and 
the resources it consumes. Or in other words, is it worth it?11, 12 
In chapter 5 we present the cost-effectiveness results of the VISK-study. We 
show that adding HMW-HA to usual care for knee OA in a population in the 
working age results in an improvement of the quality of life (QoL). This gain in 
QoL was accompanied with a cost increase in the HMW-HA treated subjects. 
The gain in QoL and costs resulted in an incremental cost-effectiveness 
ratio (ICER) of approximately €9,100 per quality adjusted life year (QALY) 
gained from the societal perspective (productivity costs and medical costs 
included). From the health care perspective (medical costs only) the ICER 
was approximately €8,700/QALY gained. The uncertainty analyses indicated 
a probability of 99% that HMW-HA in knee OA will result in positive health 
effects. Considering a maximum willingness to pay of €20,000/QALY for 
the treatment of knee OA and similar conditions, the probability on cost-
effectiveness of HMW-HA is 64% from the societal perspective and 86% from 
the health care perspective.13-15
To date, no other economic evaluations on the cost-effectiveness of HA in 
knee OA for the Dutch situation have been published. The economic results 
of the VISK study are in line with 2 other RCTs from France and Canada 
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investigating the cost-effectiveness of HMW-HA added to usual care for knee 
OA. Favorable ICERs were reported for the situation of the country in which 
the study was performed, both in a population with higher average age and in 
which a higher percentage of subjects was not involved in a paid occupation 
compared to our study.9, 16 
A systematic review on the cost-effectiveness of intra-articular HA and 
disease-modifying drugs (DMOADs) in knee OA reported similar results. In 
the included RCT studies the authors report that the ICERs varied between 
€4390 and €13450 per QALY. This study included placebo controlled RCTs as 
well as RCTs with a head to head comparison of 2 or more HA derivatives.17
In the VISK study we included patients with mild to moderate knee OA aged 
between 18 and 65, the latter being the pensionable age in The Netherlands at 
time of the study. As a consequence 75% of the participants were involved in 
paid employment. In musculoskeletal disorders the productivity costs generally 
exceed the medical costs.18-20 In chapter 3 we show that the productivity costs 
of the working part of the VISK population prior to their participation in the 
study where 5 times higher than the medical costs. It is very well possible that 
the incremental costs associated with the addition of HMW-HA to usual care 
for mild to moderate knee OA in the general and older knee OA population are 
lower due to a smaller proportion of patients in paid employment, leading to a 
more favorable ICER than currently reported on in chapter 5.
In The Netherlands, the national Health Institute (Zorginstituut Nederland) 
advises the minister of Health, Welfare and Sports on the reimbursement 
of medical treatments by health insurance companies. Advises on 
reimbursement are based on 4 criteria: necessity (is there a health problem?); 
effectiveness (is there a treatment that can solve the health problem?); cost-
effectiveness (is there an acceptable relation between health effects and 
costs?); and practicability (are the costs out of reach of the individual, and 
within reach of society?).21 
Intra-articular therapy with HA for knee OA is currently not reimbursed in 
The Netherlands. 22 This decision is based on the most recent Dutch medical 
specialists guideline on the non-surgical treatment of knee and hip OA, which 
does not recommend intra-articular HA for reasons of limited efficacy and 
the absence of proven cost-effectiveness.23, 24  
As we showed in chapter 4 and 5, intra-articular HA therapy results in beneficial 
148 Chapter 7
effectiveness results, a favorable ICER, a high probability of positive healthcare 
effects and a high probability on of cost-effectiveness. Based on these results, 
and given the decision tree used by the Health Institute to establish an advise 
on reimbursement, we believe that reasons exist to reconsider the current 
advise not to reimburse HA for the treatment of knee OA.14, 21
Guidelines and HA
Intra-articular HA as a treatment modality is not unambiguously 
recommended in the various clinical practice guidelines on the treatment of 
knee OA.  Some guidelines recommend against its use in the treatment of 
knee OA, some guidelines regard intra-articular HA appropriate under certain 
circumstances, and some guidelines provide an uncertain recommendation 
or even no recommendation at all.25-28  The most recent Dutch medical 
specialists guideline on the non-surgical treatment of knee and hip OA does 
not recommend intra-articular HA as a standard treatment option for knee 
OA for reasons of limited efficacy and absence of proven cost-effectiveness.23, 
24  The Dutch general practitioners association also does not recommend the 
intra-articular HA in the treatment of knee OA.29
Given the effectiveness and cost-effectiveness results of the VISK study 
(chapter 4 and 5) we advocate for the recommendation of intra-articular 
HMW-HA as treatment option in guidelines on the management of 
symptomatic knee OA. 
Several methodological issues are held responsible for the variety in 
guideline recommendations on HA in knee OA. Inconsistency in work group 
composition and recommendation formation is reported to contribute to the 
difference in clinical practice guideline recommendations. Also, differences in 
the process of evidence assessment and evidence inclusion play an important 
role in the variation in the guideline recommendations.25  
An important issue is that there is often a difference in the benefits observed 
in clinical practice and the treatment effects as assessed with placebo 
controlled RCTs. This is called the efficacy paradox.30, 31 In clinical practice, 
when a patient receives a treatment the benefits experienced not only 
result just from the specific treatment effects but also from what are called 
contextual effects from receiving the treatment.30, 31 These contextual effects 
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comprise the placebo effect, but also the Hawthorn effect (the effect due 
to being observed) and/or spontaneous effects (e.g. disease fluctuation or 
regression to the mean).30, 32 Treatment effect and contextual effects may 
interact and influence the magnitude of the observed improvement seen.30 
Treatment guidelines generally focus on specific treatment effects as 
assessed by means of placebo controlled RCTs. A certain treatment with a 
large effect due to strong nonspecific effects is generally considered less 
adequate in this matter, compared to a treatment with lesser total effects 
but with a stronger specific treatment effect.30, 31 This results in a disconnect 
between guidelines, including the treatment guidelines on the non-surgical 
treatment of knee OA, and the actual clinical practice in everyday care.30
Another explanation for the variety in recommendations on the use of 
intra-articular HA for the treatment of knee OA is that in most studies and 
reviews on the efficacy, HA and available HA derivatives are considered as 
one treatment or one group. Nevertheless, HA-derivatives for therapeutic 
use in knee OA differ from each other in several ways. Intra-articular HA for 
clinical use can be produced by either bacterial fermentation or extraction 
from avian tissue.33 The molecular weight of HA-derivatives varies (mostly 
between 500 to 6000 kiloDalton (kDa)). In order to further increase molecular 
weight the molecular structure can be chemically crosslinked to form so-
called Hylans.34-36 The volumes and frequency of injections varies and some 
derivatives include additives like mannitol or sorbitol.37 
These differences result in clinical and also economic consequences. 
Subgroup analyses in previous meta-analyses on the efficacy of HA show that 
HMW-HA is more efficacious than LMW HA.4, 38 A recent systematic review 
investigating the product differences between intra-articular HA derivatives 
concluded that product differences influence both efficacy and safety. The 
authors report that intra-articular HA products should not be treated as a 
group due to these differences. Based on their findings the authors conclude 
that HMW HA-derivatives and products derived from biological fermentation 
relate to superior efficacy and safety.35 In chapter 6 we show that the 
higher risk on local AEs after the administration of local intra-articular HA is 
associated with the use of non-crosslinked HA-products and products with a 
lower molecular weight.
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Comparison with other non-surgical treatment modalities
Several treatment modalities for the non-surgical treatment of symptomatic 
knee OA are available.  
A network meta-analysis compared common pharmacological interventions 
for knee OA.39 Interventions and comparators were investigated, including 
oral acetaminophen, diclofenac, ibuprofen, naproxen and celecoxib, intra-
articular corticosteroids and HA and oral and intra-articular placebo. Intra-
articular HA was found to be the most efficacious treatment in pain reduction 
compared to the other interventions and the placebo comparators. On the 
improvement of function, intra-articular hyaluronic acid was statistically 
significantly better than intra-articular corticosteroids and oral or intra-
articular placebo. No statistically significant differences in function were 
found in the comparison with oral treatments like acetaminophen, diclofenac, 
ibuprofen, naproxen or celecoxib.39
These results are in line with the results of a systematic review on overlapping 
meta-analyses on the comparison of HA versus other (non-surgical) 
therapies in the treatment of knee OA. This study reports that intra-articular 
corticosteroids are relatively more effective in pain relief than HA in the first 4 
weeks after intra-articular administration. After this period, intra-articular HA 
results in greater efficacy with residual effects up to 26 weeks post-injection. 
Compared to oral non-steroidal anti-inflammatory drugs (NSAIDs), the efficacy 
of intra-articular HA on knee pain and function does not differ significantly. 
Intra-articular platelet-rich plasma (PRP) led to similar but more robust long 
term positive effects on knee function compared to intra-articular HA without 
a difference in AEs.40 
Due to the risk of gastrointestinal side effects, the safety profile of intra-
articular HA was considered more favorable than that of oral NSAIDs. Overall, 
the authors conclude that the current highest level of evidence suggests that 
IA-HA is a viable option for knee OA due to improvements in knee pain and 
function up to 26 weeks and a good safety profile.40
Economic evaluations of other non-surgical treatments for knee OA 
in the Dutch situation are scarce. One study from The Netherlands 
compared behavioral graded activity therapy to usual care as provided by 
physiotherapists in patients with hip or knee OA. At 65 weeks, no differences 
were found between the two groups in improvement with respect to baseline 
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on any of the outcome measures. The authors conclude that the study 
provides no evidence that behavioral graded activity is either more effective 
or less costly than usual care from physiotherapists for hip or knee OA.41
A study from New Zealand investigated the cost effectiveness of providing 
supervised physiotherapy in addition to usual medical care in patients 
with osteoarthritis of the hip or knee. After 2 years follow-up, the authors 
concluded that individually supervised exercise therapy is cost-effective and 
clinically effective in addition to usual medical care, and leads to cost savings 
for the health system and society.42
A systematic review on the cost-effectiveness of nonpharmacological 
nonsurgical interventions for hip and/or knee OA reported that there is 
only limited evidence for the cost-effectiveness of conservative treatments 
like exercise programs, acupuncture, rehabilitation programs, and lifestyle 
interventions for the management of hip and/or knee OA.43 Another systematic 
review investigated the cost-effectiveness of adjunct non-pharmacological 
interventions for knee OA. Acupuncture, braces, heat treatment, insoles, 
interferential therapy, laser/light therapy, manual therapy, neuromuscular 
electrical stimulation, pulsed electrical stimulation, pulsed electromagnetic 
fields, static magnets and transcutaneous electrical nerve Stimulation (TENS) 
where all investigated. The authors conclude that TENS is cost-effective when 
a £20,000 per QALY threshold is used, with an ICER of £2,690 per QALY. If 
only higher quality trials are considered, acupuncture is cost-effective at this 
threshold with an ICER of £13,502 per QALY.44
Who will benefit?
An important matter in the decision making process on whether or not to opt 
for treatment with intra-articular HA is to know which patient will benefit most 
from the treatment. Nevertheless, the magnitude of the effect of treatment 
with intra-articular HA among different phenotypes of knee OA patients is 
unclear.2 Subgroup analyses are generally not included in the individual 
studies and meta-analyses on the efficacy of HA in knee OA.
Evidence suggests that intra-articular treatment with HA is more effective 
in specific patient groups.2, 45, 46 Results from individual studies show that 
patients with a mild radiological degree of OA (Kellgren & Lawrence (K&L) 
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grade II rather than III), patients under 60 years old, patients with a high level 
of symptoms, and the absence of effusion of the knee joint is related to more 
beneficial clinical results. The presence of crystals in the knee joint does 
not appear to prohibit the use of HA injections or reduce the level of 
response.2, 45
These results are in concordance with the findings we present in chapter 4. 
In this chapter we show that that HMW-HA added to the usual non-surgical 
care for knee OA is effective in a relatively younger patient group with an 
average age of 54, with K&L grade I to III and a mean pain score of 4.8 out of 
10 during rest. 
A recent post-hoc analysis of a non-inferiority randomized controlled trial 
comparing 2 different HA-derivatives showed that obesity and radiological 
severity were significantly associated with failure of treatment with intra-
articular HA. Failure was defined in this study as not being responder to therapy 
at 6 months according to OMERACT-OARSI criteria.47 In a subsequent study 
the authors report that despite these results, evidence shows that particular 
subgroups of patients with obesity and advanced joint space narrowing still 
may benefit from intra-articular treatment with HA.48  
It is very well possible that these results are subjected to bias, since both BMI 
and radiological severity of knee OA are also associated with progression of 
knee OA itself.49
Based on a systematic research of evidence, expert clinical opinion, and 
current evidence-based clinical practice guidelines a workgroup of clinical 
experts developed appropriate use criteria for HA therapy in the treatment 
of knee OA.50 Intra-articular HA therapy was deemed appropriate for 
patients with confirmed radiological and clinical mild to moderate knee OA, 
who have not received other therapies for the knee, who have failed other 
non-pharmacologic or pharmacologic therapies, or who have incomplete 
response to other therapies for the knee. Treatment with HA in patients with 
severe knee OA was deemed uncertain, as was the treatment of patients with 
high risks to AEs or who are contraindicated for pharmacological agents for 
the knee.50
From an economic point of view the results if the VISK study (chapter 5) 
show that intra-articular HA added to UC in the treatment of knee OA results 
in a favorable ICER and a high probability on cost-effectiveness in relatively 
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younger patients with mild to moderate clinical knee OA.13 No evidence from 
clinical studies is available on the costs or cost-effectiveness associated with 
HA treatment in certain patient subgroups.
Limitations
The backbone of this thesis is formed by the VISK study and its outcomes on 
effectiveness and cost-effectiveness as presented in chapters 4 and 5. With 
the VISK study we aimed to evaluate the effectiveness and cost-effectiveness 
of intra-articular HA for knee OA by means of a pragmatic RCT in which health 
and cost outcomes are measured in real life conditions.51 
The target population of the VISK study can be described as patients in 
the working age with symptomatic and mild to moderate knee OA. For this 
reason, patients with K/L grade I to III and a minimal pain score of 2 were 
included and, for example, patients who were more likely to benefit from 
different kinds of therapy were excluded (e.g., K&L grade IV, substantial varus 
or valgus deformation). Other in- and exclusion criteria were applied to avoid 
measuring effects strongly related to other factors than the intervention 
itself (e.g. recent or planned knee surgery) or to avoid possible harm due to 
the intervention (e.g. pregnancy or allergies).  Any characteristic of a patient 
or setting that impacts the benefit or risk of a treatment will inevitably affect 
generalizability if that characteristic differs between the trial population and 
the patient group where the results eventually are applied to.12, 51 So whether 
the results of the VISK study also extend to other patient groups who might 
benefit from HMW-HA treatment (e.g. patients with more severe knee OA or 
patients not fit for surgery) remains uncertain. 
As is common in cost-effectiveness analyses alongside RCTs, the sample 
size of the VISK study was based on the primary clinical outcomes.8, 16, 52-55 
Ideally, the sample size calculation would also be based on expected costs 
and QoL differences.56 In practice this would result in large required sample 
sizes which are difficult to include. The economic results of the VISK study 
therefore must be interpreted in light of the sample size discussion.
In an economic evaluation of a certain interventions alongside a clinical 
trial the focus generally lies on the assessment of the associated medical 
costs and productivity costs.16, 54, 55 Potentially long term personal costs 
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due to possible premature retirement, loss of income and/or subsequent 
reductions in personal savings are not accounted for in these types of studies, 
nor are national costs related to disability benefits, welfare benefits or lost 
tax revenues.57, 58 Although these costs are estimated to be substantial and 
relevant to fully understand the economic consequences of an intervention, 
the design of the VISK study did not allow for the assessment of these costs.
Recommendations for future research
Most research on the efficacy (and effectiveness) of intra-articular HA in knee 
OA has focused on the administration of a single series of HA. The peak 
effectiveness of a series of intra-articular HA lies between 1 and 2 months 
and residual effects exist up to 6 months.6, 45, 59 A recent systematic review on 
the topic reported that repeated courses were demonstrated to maintain or 
further improve pain reduction while introducing no increased safety risk.5 
Future research should investigate whether or not these positive health 
effects also result in beneficial economic results in terms of cost-effectiveness. 
The impact of intra-articular HA on long-term outcomes like delay of TKR has 
been studied in healthcare claims databases.10, 46  These studies report that 
the time from initial diagnosis to the date of TKR surgery is significantly longer 
in knee OA patients treated with intra-articular HA, compared to patients who 
were not treated with HA.10, 46 Due the possibility of confounding by indication 
these results need to be interpreted with reserve and prospective research 
in controlled studies is needed to investigate the influence of intra-articular 
HA on the delay of TKR surgery.
There is limited evidence on which knee OA patients might benefit more 
from intra-articular HA therapy and in which patients this therapy might 
fail2. A mild radiological degree of OA, age under 60 years, a high symptom 
level and the absence of knee effusion is reported to be associated with 
beneficial clinical outcomes and obesity and more advanced radiological OA 
appear to be associated with failure of treatment with intra-articular HA.2, 
45-47 The authors reporting on the latter findings in a following study show 
that particular subgroups of patients with obesity and advanced joint space 
narrowing still may benefit from intra-articular treatment with HA.48 Since pain 
in knee OA can be from nociceptive as well as neuropathic origin, different 
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pain phenotypes might be the main reason for the success or failure of intra-
articular therapy with HA.48
These results illustrate that more research is needed to answer the question on 
which knee OA patients, with which phenotypic pain characteristics, are more 
likely to benefit from treatment with intra-articular HA.2 Given the availability 
of numerous studies on intra-articular HA in knee OA such subgroup analyses 
might be best performed by means of a meta-analysis of individual patient 
data, rather than by a meta-analysis using aggregate data only.60
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Summary
Osteoarthritis (OA) is a chronic disease of the knee joint, causing pain, joint 
stiffness and functional impairment. Next to health impairment, OA results 
in serious economic consequences. Knee OA accounts for the vast majority 
of the burden of disease of OA. The treatment of knee OA is symptomatic. 
One of the non-surgical treatment modalities for knee OA is intra-articular 
injection therapy with hyaluronic acid (HA), which leads to pain reduction and 
improvement of knee function. This thesis focuses on various aspects of the 
effectiveness as well as the efficiency of intra-articular HA as a non-surgical 
treatment modality for patients with knee OA.
In chapter 2 we present the results of a systematic review on the accuracy 
of different approaches for intra-articular injections in the knee joint. We 
systematically reviewed the literature and assessed the possible risk of bias 
of the 9 included studies. The analyses show that superolateral injection 
approach with the leg in extension was resulted in the highest pooled accuracy 
of 91%. Approaches like the lateral midpatellar approach, the anterolateral 
approach and the anteromedial approach resulted in the lowest pooled 
accuracy rates. We conclude that for a blindly performed intra-articular 
needle placement in the knee joint, the superolateral approach should be the 
approach of choice. Since this approach still results in a substantial amount 
of extra-articular needle placements, guidance by imaging techniques during 
the injection procedure may enhance the accuracy. 
In chapter 3 we present the results of a cross-sectional study in which 
aimed to identify and quantify the productivity costs and medical costs in 
knee OA patients with a paid employment. We investigated the possible 
associations between productivity losses and various patient, health, and 
work characteristics. 
The investigated study subjects participated in a randomized controlled trial 
(RCT) investigating the effectiveness and cost-effectiveness of intra-articular 
hyaluronic acid in addition to usual care: the VISK study. Non-surgically 
treated patients with mild to moderate knee OA and aged 18-65 years were 
included in this RCT.  The included study subjects in this cross-sectional study 
consisted of the patients of the RCT that were involved in paid employment. 
We analyzed the data acquired from the baseline measurement of this 
RCT that referred to the previous 3 months, before the onset of any trial 
163Summary
intervention. In total, 117 patients of the included patients of the VISK study 
were involved in paid employment at the time of inclusion. We show that the 
total knee-related productivity costs and medical costs were €871 per patient 
per month, of which the total productivity costs were €722 and the total 
medical costs were €149. The analyses show that reduced productivity while 
being present at work was responsible for the majority (of the productivity 
costs. Performing physically intensive work and experiencing more pain 
during activity were significantly associated with the productivity losses. We 
conclude that the total knee-related productivity costs and medical costs of 
conservatively treated symptomatic knee OA patients with paid employment 
in The Netherlands are €871 per patient per month, of which the productivity 
costs account for 83% and the medical costs for 17% of these total costs.
To investigate the effectiveness and the cost-effectiveness of intra-articular 
HA in the non-surgical treatment regime of knee OA the VISK study was 
designed. In this open-labelled RCT, patients between 18 and 65 with mild to 
moderate symptomatic knee OA were randomized to either the intervention 
group, who received 3 weekly injections with a high molecular weight (HMW) 
HA derivative added to the usual non-surgical care for knee OA, or in the 
control group who received the usual care only. In total, 156 study subjects 
were included in the VISK study, of which 77 were randomized to the 
intervention group and 79 to the control group.
In chapter 4 the clinical effectiveness results of the VISK study are presented. 
The primary clinical outcome parameters were defined as response to 
therapy at 52 weeks follow-up according to OMERACT-OARSI criteria. This is a 
variable in which the results of changes after treatment in three symptomatic 
domains (pain, function, and patient global assessment (PGA)) are combined 
to a single variable. The secondary outcome comprised the between group 
difference on the individual responder domains pain, function and PGA. The 
results show that adding intra-articular HA to the usual care for knee OA 
leads to significantly more responders to therapy compared to usual care 
only. In the intervention group 57.1% was responder to therapy versus 34.2% 
in the control group when pain during activity included in the responder 
domains, and 54.5% versus 34.2% when pain during rest was included in the 
responder domains. The results of the secondary outcome analyses show 
that the scores on individual responder domains over all follow-up moments 
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were statistically significant in favour of the intervention group in the domains 
pain during rest, knee related function and PGA. Based on these results we 
conclude that intra-articular HMW-HA added to usual care is an effective 
treatment strategy for knee OA patients in the working age.
In chapter 5 the results of the economic evaluation of the VISK study are 
presented. We performed a cost-utility analysis over 52 weeks follow-up in 
order to determine the cost-effectiveness of intra-articular HA added to the 
usual non-surgical care for knee OA patients. The primary health economic 
outcome was determined by the between group difference in quality-
adjusted life years (QALYs) and costs. To determine the amount of QALYs the 
area under the curve of the quality of life scores as measured by the EuroQol 
questionnaire over 52 weeks was calculated. The between group differences 
in costs and QALYs were expressed in a so-called cost-effectiveness ratio 
(ICER). This ratio is interpreted as the additional costs per gained QALY due to 
the addition of intra-articular HA to the usual care. Given various thresholds 
for the maximum willingness to pay for 1 QALY gained, the probability of 
cost-effectiveness of intra-articular HA therapy for knee OA was indicated 
on an acceptability curve. The results show that the total of productivity and 
medical costs was €475 higher in the intervention group. The intervention 
group gained more QUALYs during follow-up compared to the control group 
(0.779 versus 0.727). This resulted in an ICER of €9.100/QALY from a societal 
perspective (productivity costs and medical costs included) and €8.700/
QALY from a health care perspective (only medical costs included). When the 
maximum willingness to pay for conditions similar to knee OA is considered, 
the probability on cost-effectiveness of the addition of intra-articular HA to 
usual care is 64% from the societal perspective and 86% from the healthcare 
perspective. We conclude that the treatment with intraarticular HMW-HA 
in knee OA patients in their working years is probably cost-effective for the 
Dutch health care situation.
In chapter 6 we report on the results of a systematic review and meta-
analysis on the adverse events (AE) of intra-articular treatment with HA for 
knee OA. We investigated the difference in local AEs, non-local AEs and study 
withdrawal in subjects treated with intra-articular HA for knee OA compared 
to their controls. Subsequently, we investigated the association with specific 
HA-product characteristics and the number of injections administered in 
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case of a statistically significant difference. The analyses of the 33 included 
articles show that treatment with intra-articular HA for knee OA results in 
more local AEs like flares or flare like symptoms, compared to placebo. It 
does not result in more non-local AEs or more study withdrawals. The higher 
risk on local AEs is associated with the use of non-crosslinked HA-products 
and products with a lower molecular weight.
Chapter 7 discusses the main findings of the research in this thesis. We 
discuss the possible implications of the VISK study results in relation to 
current clinical treatment guidelines for knee OA the current advise on 
reimbursement of intra-articular HA for the treatment of knee OA. The 
limitations of the presented research in this thesis are addressed. Implications 
from a clinical as well as from a health-economic point of view are discussed 
as well as possible directions for future research.
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Artrose is een chronische ziekte van het kniegewricht die pijn, stijfheid en 
belemmeringen in het functioneren veroorzaakt. Naast gezondheidsklachten 
heeft artrose ook forse economische consequenties. Van alle gewrichten 
geeft artrose van de knie de grootste ziektelast. De behandeling van 
knieartrose is symptomatisch. Eén van de conservatieve behandelopties voor 
artrose is intra-articulaire injecties met hyaluronzuur (HA). Deze behandeling 
wordt gegeven ter vermindering van pijn en verbetering van de functie van 
de knie. Dit proefschrift focust op diverse aspecten van zowel effectiviteit als 
doelmatigheid van intra-articulaire injecties met HA als behandelmodaliteit 
voor patiënten met knieartrose.
In hoofdstuk 2 worden de resultaten van een systematische review 
gepresenteerd over de accuratesse van verschillende benaderingen van 
intra-articulaire injecties in het kniegewricht. Middels een systematische 
zoekactie werd in de verschillende databases gezocht naar geschikte 
wetenschappelijke publicaties. Het mogelijke risico op vertekening van de 
onderzoeksresultaten van de 9 geïncludeerde studies werd beoordeeld. De 
analyses laten zien dat de superolaterale injectie benadering met het been 
gestrekt de hoogste gepoolde accuratesse van 91% opleverde. Benaderingen 
zoals midpatellair, anterolateraal en anteromediaal resulteerden in de laagste 
gepoolde accuratesse. We hebben geconcludeerd dat de superolaterale 
benadering voor een intra-articulaire injectie in de knie de benadering 
van keuze is. Omdat bij deze benadering nog steeds 9% van de injecties 
buiten het kniegewricht terecht komt kan het gebruik van beeldvormende 
technieken tijdens de procedure mogelijk de accuratesse verhogen.
In hoofdstuk 3 presenteren we de resultaten van een cross-sectionele 
studie waarin we productiviteitskosten en medische kosten van knieartrose 
patiënten hebben geïdentificeerd en gekwantificeerd. We onderzochten de 
mogelijke associaties tussen dit verlies van productiviteit en verschillende 
karakteristieken van de patiënten zelf, hun gezondheid en het werk. De 
onderzochte studiepopulatie was onderdeel van een gerandomiseerd en 
gecontroleerd onderzoek (RCT) waarin de effectiviteit en kosteneffectiviteit 
van intra-articulair HA toegevoegd aan de standaard zorg werd onderzocht: 
de VISK studie. Conservatief behandelde patiënten met milde tot matige 
knieartrose in de leeftijd van 18-65 jaar namen deel aan deze studie. 
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De geïncludeerde patiënten in het cross-sectionele onderzoek waren 
deelnemers aan de VISK-studie met een betaalde baan. We hebben de data 
van de nulmeting van de VISK-studie geanalyseerd in deze groep. Deze data 
gaf de situatie weer van de periode van 3 maanden vóór de nulmeting tot 
aan de nulmeting zelf. De geïncludeerde deelnemers namen in die periode 
nog niet actief deel aan de VISK studie. In totaal hadden 117 van de 156 
deelnemers aan de VISK studie een betaalde baan en werden geïncludeerd in 
de huidige studie. Uit de metingen blijkt dat het totaal aan knie gerelateerde 
productiviteitskosten en medische kosten €871 per werkende deelnemer 
per maand bedraagt. De productiviteitskosten bedroegen €722 en de 
medische kosten bedroegen €149. Uit de analyses blijkt dat de verminderde 
productiviteit op het werk verantwoordelijk is voor de meerderheid van de 
productiviteitskosten. Het hebben van fysiek zwaar werk en het hebben 
van meer pijnklachten tijdens activiteiten waren statistisch significant 
geassocieerd met productiviteitsverlies. We hebben geconcludeerd dat 
het totaal aan knie gerelateerde productiviteitskosten en medische kosten 
van werkende conservatief behandelde knieartrose patiënten in Nederland 
€871 per patiënt per maand bedraagt. Deze kosten bestaan voor 83% uit 
productiviteitskosten en voor 17% uit medische kosten. 
De VISK-studie is ontworpen om de effectiviteit en efficiëntie van intra-articulair 
hyaluronzuur in het niet-operatieve behandeltraject van knieartrose te 
onderzoeken. In dit open-label gerandomiseerde onderzoek werden patiënten 
tussen de 18 en 65 jaar met milde tot matige knieartrose gerandomiseerd 
in de interventie groep of de controle groep. De interventiegroep kreeg 3 
wekelijkse injecties met een hoog moleculair gewicht (HMW) HA preparaat 
toegevoegd aan de gebruikelijke niet-operatieve zorg voor knieartrose. De 
controle groep kreeg alleen de gebruikelijke niet-operatieve zorg. In totaal 
werden 156 patiënten geïncludeerd in de VISK studie, waarvan 77 patiënten 
gerandomiseerd werden in de interventie groep en 79 patiënten in de 
controle groep.
In hoofdstuk 4 worden de resultaten van de VISK studie gepresenteerd met 
betrekking tot de effectiviteit. De primaire klinische uitkomst parameter werd 
gedefinieerd als de zogeheten ‘respons op behandeling’ na de volgperiode van 
52 weken, conform de OMERACT-OARSI criteria. In deze uitkomst parameter 
worden de resultaten van uitkomsten op 3 symptomatische domeinen (pijn, 
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functie, globale patiënten beoordeling (PGA) ) gecombineerd tot 1 variabele. 
De secundaire klinische uitkomstmaten bestaan uit het verschil tussen de 
randomisatiegroepen in de individuele respons domeinen pijn, functie en 
PGA. Uit de resultaten blijkt dat het toevoegen van intra-articulair HA aan 
de gebruikelijke zorg voor knieartrose leidt tot statistisch significant meer 
respons op de behandeling. Wanneer pijn gedurende activiteit in de respons 
domeinen was opgenomen, was 57.1% van de patiënten in de interventiegroep 
respondent na de behandeling versus 34.2% van de patiënten in de controle 
groep. Wanneer pijn in rust in de respons domeinen was opgenomen was 
54.4% van de patiënten in de interventiegroep respondent na de behandeling 
versus 34.2% in de controlegroep. De resultaten van de secundaire analyses 
laten zien dat de scores op de individuele respons domeinen op alle volg 
momenten statistisch significant waren ten faveure van de interventiegroep 
in de domeinen pijn tijdens rust, knie gerelateerde functie en PGA. Op basis 
van deze resultaten hebben we geconcludeerd dat intra-articulair HMW-HA 
toegevoegd aan de gebruikelijke zorg een effectieve behandeling is voor 
knieartrose patiënten in de werkende leeftijd.
In hoofdstuk 5 worden de resultaten van het economisch deel van de 
VISK-studie gepresenteerd. Een kosten-utiliteitsanalyse werd uitgevoerd 
om de kosteneffectiviteit van het toevoegen van intra-articulair HA aan 
de conservatieve behandeling van knieartrose te bepalen. De primaire 
gezondheidseconomische uitkomstmaat werd bepaald door het verschil in 
voor kwaliteit van leven gecorrigeerde levensjaren (QALY) en kosten tussen 
beide studiegroepen. Om het aantal QALY’s te bepalen werd de oppervlakte 
onder de kromme van de grafiek van de kwaliteit van leven scores, zoals 
gemeten met de EuroQol vragenlijst, over 52 weken berekend. De verschillen 
tussen beide groepen in kosten en QALY’s werden uitgedrukt in een 
zogeheten kosten-batenverhouding (ICER). In deze ratio komen de additionele 
kosten per gewonnen QALY als gevolg van de toevoeging van intra-articulair 
HA aan de gebruikelijke behandeling tot uiting. Op basis van verschillende 
drempelwaardes van betalingsbereidheid voor 1 gewonnen QALY werd de 
mate van waarschijnlijkheid van kosteneffectiviteit van intra-articulaire therapie 
met HA uiteengezet in een aanvaardbaarheidscurve. Uit de resultaten blijkt 
dat het totaal van productiviteitskosten en medische kosten €475 hoger was 
in de interventiegroep. In de interventiegroep werden meer QALY’s gewonnen 
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in vergelijking met de controlegroep (0.779 versus 0.727). Dit resulteerde 
in een ICER van €9.100/QALY vanuit het maatschappelijk perspectief 
(productiviteitskosten en medische kosten meegenomen) en €8.700/QALY 
vanuit het medisch perspectief (alleen medische kosten meegenomen). 
Wanneer de betalingsbereidheid voor aandoeningen vergelijkbaar met 
knieartrose wordt beschouwd dan is de waarschijnlijkheid van kosteneffectiviteit 
van de toevoeging van intra-articulair HA aan de gebruikelijke zorg vanuit een 
maatschappelijk perspectief 64% en vanuit een medisch perspectief 86%. We 
concludeerden dat de behandeling met intra-articulair HMW-HA in knieartrose 
patiënten in de werkende leeftijd waarschijnlijk kosteneffectief is binnen de 
Nederlandse gezondheidszorg situatie. 
In hoofdstuk 6 presenteren we de resultaten van een systematisch review 
en meta-analyse over de bijwerkingen van intra-articulaire behandeling 
van knieartrose met HA. Alleen placebo-gecontroleerde studies werden 
geïncludeerd. We onderzochten de verschillen in lokale bijwerkingen en 
systemische bijwerkingen in studiedeelnemers die behandeld werden 
met intra-articulair HA en vergeleken dit met de controlegroepen. We 
onderzochten tevens de verschillen tussen beide groepen in het aantal 
deelnemers dat de studiedeelname staakte. Wanneer een verschil statistisch 
significant was, onderzochten we vervolgens de associatie met specifieke 
productkarakteristieken van HA en het aantal toegediende injecties met HA. 
De analyses van de 33 geïncludeerde studies laten zien dat behandeling van 
knieartrose met intra-articulair HA resulteert in een statistisch significant 
hoger risico op meestal kortdurende opvlammingen van knieklachten 
zoals pijn, stijfheid en zwelling in vergelijking met placebo (risico ratio (RR) 
1.26, p=0.001). Er is geen statistisch significant hoger risico op systemische 
bijwerkingen of op het vaker stoppen van studiedeelname door deelnemers. 
Uit de multivariate analyses blijkt dat het hogere risico op lokale bijwerkingen 
statistisch significant is geassocieerd met het gebruik van HA producten 
zonder moleculaire kruisverbinding (RR 3.93, P<0.001) en producten met 
een lager molecuulgewicht (RR 1.08, P<0.001). We concludeerden dat intra-
articulair HA in de behandeling van knieartrose leidt tot een hoger risico op 
lokale bijwerkingen en dat dit risico geassocieerd is met het toedienen van 
HA producten zonder moleculaire kruisverbinding en producten met een 
lager molecuulgewicht.
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In hoofdstuk 7 worden de belangrijkste bevindingen van dit proefschrift 
besproken. De mogelijke implicaties van de VISK-studie resultaten voor 
de huidige behandelrichtlijnen voor knieartrose worden besproken 
evenals voor het huidige vergoedingsbeleid van intra-articulair HA voor 
de behandeling van knieartrose. De beperkingen van de gepresenteerde 
onderzoeksresultaten worden besproken. Implicaties vanuit klinisch en 
vanuit gezondheidseconomisch oogpunt worden aangegeven en tevens 
worden mogelijkheden voor toekomstig onderzoek besproken.
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